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Abstract  
Changes in Gait, Balance, and Function with Vestibular Rehabilitation 
Susan P. Barker 
William Freedman, PhD 
 
 
 
One of the most common functional deficits encountered by physical therapy 
clinicians is gait dysfunction.  If physical therapists are to make evidence-based decisions 
in the clinical management of patients with gait dysfunction, they need the ability to 
measure spatiotemporal gait variables validly and reliably.  A gait analysis system that is 
relatively inexpensive and portable is the GaitMat II (GM).  Several studies were 
undertaken to examine reliability and validity of the GM.  Three different GM systems 
were compared with regard to placement of their switches.  Although variability was 
present, error analysis demonstrated that the variability in switch placements was much 
less than the normal variability of most gait variables measured with the GM.  Another 
study compared the accuracy and reliability of measures taken with the GM system with 
the same measures taken simultaneously with the Vicon motion analysis system.  Results 
indicated excellent agreement between the GM and Vicon systems for timing variables 
but poor agreement between the measures for distance variables.  The mean difference 
between the measures for distance variables was 11.7 mm, an error amount that would 
have little clinical significance in adults for distance measures such as step length or 
stride length.  Another study examined the validity of gait measures collected with the 
GM from patients with a diagnosis of unilateral vestibular hypofunction (UVH) before 
and after they participated in vestibular rehabilitation and compared these values with 
those collected from a matched group of subjects without vestibular pathology.  The 
change in gait variables after vestibular rehabilitation was compared with the change in 
xiv 
Dizziness Handicap Inventory scores and computerized posturography composite scores.  
No significant difference was found following vestibular rehabilitation in any gait 
variable in this sample.  In this sample, gait variables measured with the GM were not 
affected by vestibular rehabilitation in the same manner as other clinical measures.  A 
discriminant analysis demonstrated that gait data collected with the GaitMat II can 
classify subjects without vestibular pathology with 100% accuracy and subjects with 
UVH with 90.9% accuracy. 
In summary, the results of these studies support the reliability and validity of the 
GaitMat II as a clinical gait analysis tool.
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CHAPTER 1: INTRODUCTION 
One of the most common functional deficits encountered by physical therapy 
clinicians is gait dysfunction.  Gait dysfunction can be caused by a variety of physical 
impairments, such as loss of joint motion, decreased sensation, and abnormal timing of 
muscle activation, as a result of myriad diagnoses.  At this time, the most readily 
accessible means of gait data collection available to the physical therapist is visual 
observation.  In most cases, decision-making about the cause of gait dysfunction for a 
given patient and treatment for the impairment are currently based on clinical observation 
and experience. 
If physical therapists are to make evidence-based decisions in the clinical 
management of patients with gait dysfunction, they need the ability to measure 
spatiotemporal gait variables validly and reliably.  Valid and reliable gait measurement is 
possible with computerized motion analysis systems, but these systems are generally 
available only in isolated gait study laboratories, not in the clinics or patient homes where 
physical therapy intervention often occurs. 
A gait analysis system that is relatively inexpensive and relatively portable is the 
GaitMat II (GM).  The GM system is a device designed to collect spatiotemporal 
characteristics of gait. (E.Q., Inc., Chalfont, PA)  It consists of a walkway covered by an 
array of 256 by 40 switches, connected to a personal computer. The GM is manufactured 
using rectangular sheets of switches applied to the surface of the mat.  Each sheet 
contains an array of 20 by 64 switches, situated in rows and columns 15 mm apart.  The 
GM system is comprised of four panels, each 96.5 cm long x 81 cm wide.  Each panel 
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can be folded in half lengthwise for ease of transportation.  The four panels connect 
together to form a walkway 3.86 m long x 81 cm wide. 
The personal computer attached to the GM samples the state of each switch every 
five milliseconds.  In the resting state, the switches are open.  When a subject steps on the 
walkway, the subject’s weight causes the switches contacted by the foot to close.  The 
computer determines which switches are closed and when they closed, with a minimum 
possible time error of five milliseconds.  The switch closure data can be viewed directly 
or analyzed to provide common spatiotemporal gait measures including support base; 
average velocity; and left and right step length, stride length, step time, swing time, 
stance time, single support time, and double support time. 
Currently, GM systems are being used in clinics and research facilities 
worldwide.  If the GaitMat II is found to be valid and reliable, it can be used with 
confidence to provide physical therapists with spatiotemporal gait data necessary for 
making informed decisions about intervention for patients with gait dysfunction.  A 
limitation to the confident use of GaitMat II data is the lack of information about its 
accuracy, validity, and reliability. 
A group of patients who require gait examination and intervention are those with 
vestibular dysfunction.  Unfortunately, little data exists about the gait characteristics of 
these individuals, and less is known about gait changes occurring with vestibular 
rehabilitation (VR).  Knowledge of the characteristics of gait in persons with vestibular 
dysfunction is necessary for physical therapists to make clinical decisions about 
intervention strategies.  Similarly, knowledge about changes that occur with VR can be 
used to assess the effectiveness of different intervention strategies. 
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Patients with vestibular pathology present with balance and gait impairments, as 
well as visual impairments and a variety of functional deficits.  Numerous studies have 
demonstrated that individualized VR is beneficial for patients with vestibular pathology.1, 
2, 3, 4, 5, 6, 7, 8, 9  These studies have evaluated postural stability, subjective measures of 
disability, or reaction to movement, but little is known about the impact of VR on gait 
function in patients with vestibular pathology.  Researchers have begun to study elements 
of the gait of patients with vestibular pathology.9, 10, 11, 12, 13, 14, 15, 16, 17, 18 
The subjects in the current study had a vestibular diagnosis of unilateral vestibular 
hypofunction (UVH) of peripheral origin.  One study of gait in subjects with UVH used 
forefoot and heel switches to examine the timing of gait variables.10  The findings of this 
study suggest that the gait of patients with UVH is abnormal with respect to timing.  
Another study examined the gait of patients with UVH in the acute and recovery stages.11  
The researchers found gait timing abnormalities during the acute stage that returned to 
normal in the recovery stage.  These findings suggest that gait variables change during 
recovery from UVH. 
Evidence for changes in the gait of persons with UVH following individualized 
VR has also been provided by Krebs et al.9  These researchers examined changes in gait 
timing, gait speed, and center of mass stability.  Improvements in these gait variables 
were found following VR, but not following sham treatment. 
There is a need for more thorough examination of the effects of UVH on gait, 
changes in gait of patients with UVH following VR, and the relationships among gait, 
posturography, and clinical measures of balance and disability in patients with UVH 
before and after VR. 
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This paper describes several studies that examined the reliability and validity of 
the GaitMat II gait analysis system.  The first study evaluated the test-retest reliability of 
the investigator’s technique for measuring distances with electronic calipers.  The 
electronic calipers were used in a second study to compare three different GaitMat II 
systems with regard to the placement of the switches on the surface of the mats.  
Consistent switch placement on different GM systems would support the accuracy of data 
collected with a GM system.  The third study determined the “normal” variability of the 
gait variables collected by the GM, for use in analyzing the effect of measurement error 
on gait variables.  The fourth study examined the test-retest reliability of a technique for 
determining the time from heel contact to forefoot contact, a variable that was collected 
during the sixth research study.  The fifth study compared the accuracy and reliability of 
measures taken with the GaitMat II System with the same measures taken simultaneously 
with the Vicon motion analysis system.  Because the Vicon motion analysis system is a 
very accurate system and is considered the “gold standard” for gait analysis, this study 
examined concurrent validity of the GM.  The sixth study examined the validity of gait 
measures collected with the GM from patients with a diagnosis of unilateral vestibular 
hypofunction before and after they participated in VR and compared these values with 
those collected from a matched group of subjects without vestibular pathology.  The 
purpose of these studies was to determine the accuracy, reliability, and validity of the GM 
gait analysis system and to investigate the predictive validity of gait variables collected 
with the GM from a group of subjects with UVH who participated in vestibular 
rehabilitation.
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CHAPTER 2: LITERATURE REVIEW 
Reliability and Validity 
Measurements taken in the clinic are not useful if clinicians cannot be confident 
in the results of those measurements.  A term that describes level of confidence is 
trustworthiness.19  The trustworthiness of a measurement is related to its degree of both 
reliability and validity.  Reliability and validity are related but different.  Reliability is the 
extent to which a measurement is consistent and free from error.20  Validity is the extent 
to which an instrument measures what it is intended to measure.20  A measurement 
cannot be valid if it is not reliable; however, if a measurement is reliable it is not 
necessarily valid. 
Several forms of reliability can be examined.  These include intratester, test-retest, 
and intertester reliability.19  Intratester reliability is the consistency of measurements 
when one examiner takes repeated measurements of the item of interest over time.  Test-
retest reliability is the consistency of measurements of the item of interest over time.  
Intertester reliability is the consistency of measurements when more than one examiner 
takes measurements of the same item of interest. 
Several forms of validity can also be examined.  These include construct, content, 
and criterion-based validity.19  Construct or face validity is based on the conceptual 
foundation of the measurement.  It is not considered to have a high degree of scientific 
merit.20  Content validity is based on a judgment of how well the measurement reflects 
meaningful elements of the item of interest, and does not include irrelevant elements.  
Content validation requires input from a panel of experts in the area of interest.  
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Criterion-based validity is the most objective approach to validity testing.  It is based on 
how well the result of one measurement technique predicts the result of another 
measurement technique, considered the criterion measurement. 
Criterion-based validity can take two forms: concurrent and predictive.  To 
examine concurrent validity, the measurement to be validated and the criterion 
measurement are taken concurrently.  To examine predictive validity, the measurement to 
be validated is carried out, followed by an interval of time after which the criterion 
measurement is carried out.  The relationship between the two measurements is 
examined, to determine if the first measurement is able to predict the result of the 
criterion measurement. 
Reliability and Validity of Gait Measures 
Possible uses of gait measures in the clinic include identifying mechanisms 
causing a patient’s gait dysfunction, classifying the severity of a patient’s disability, 
predicting a patient’s future status, determining the need for adaptive or supportive 
equipment, and assessing the effects of interventions.21  In order to make these judgments 
with confidence, the gait analysis techniques employed by clinicians should be 
trustworthy; that is, they must be both reliable and valid. 
Relatively few studies have been published that examine the trustworthiness of 
gait measures.  Cutlip et al examined the validity of two gait analysis systems by 
comparing the spatial and temporal gait variables obtained simultaneously with the 
GAITRite® and PEAK® Motus motion measurement systems. 22  The GAITRite® 
system consists of a rubberized mat containing embedded pressure sensors.  The PEAK® 
Motus system requires reflective markers attached to the subjects’ shoes.  The PEAK® 
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software requires manual digitization on a frame by frame basis.  The mean values for all 
gait variables measured by GAITRite® were consistently larger than those measured by 
PEAK®, although Pearson product moment correlation coefficients were consistently 
greater than 0.94.  Statistically significant differences were found between the two 
systems for step length and stride velocity. 
One study used the GaitMat as the criterion measurement for a concurrent validity 
design.23  Cuffia et al compared gait data collected simultaneously with the Gait Grid 
Gait Mat (GG) and GaitMat II (GM).  The GG is a black vinyl mat, the surface of which 
is marked with lines spaced 4 cm apart.  Five raters analyzed the gait of 36 healthy 
subjects using the manufacturer’s suggested procedure.  Results were analyzed using the 
intraclass correlation coefficient.  For the GG, the ICC value for interrater reliability was 
0.99, the ICC values for intrarater reliability ranged from 0.95 to 0.97, and the ICC value 
for test-retest reliability ranged from 0.94 to 0.97.  The ICC comparing GG and GM 
results were 0.96 to 0.98, indicating excellent concurrent validity for the GG.  There are 
no published studies reporting reliability or validity data for the GaitMat II system.  
Therefore, its use as the “gold standard” for the purposes of establishing concurrent 
validity is questionable. 
Hill et al conducted a study that examined the test-retest reliability of the Clinical 
Stride Analyzer in 22 subjects with hemiplegia secondary to CVA.24  This system 
consists of inner soles with footswitches over the heel, first and fifth metatarsals, and 
great toe.  Each footswitch is sampled every 2 msec.  This study found intraclass 
correlation coefficient values > 0.85 for all temporal and distance variables of gait. 
 8
Role of the Vestibular System 
The vestibular system is comprised of the peripheral apparatus in the inner ear, 
the vestibular nuclei in the brainstem, and motor pathways that can activate trunk and eye 
muscles.  The peripheral vestibular apparatus detects head position and relays that 
information to the vestibular nuclei in the brainstem.  The vestibular nuclei activate the 
motor pathways that can activate trunk and eye muscles.  The vestibular system produces 
two important reflexes: vestibuloocular and vestibulospinal.25  Vestibuloocular reflexes 
(VOR) stabilize gaze during head movement.  VOR dysfunction leads to visual 
disturbances with head movement.  Vestibulospinal reflexes (VSR) stabilize the body.  
VSR dysfunction leads to postural control disturbances.  Vestibular pathology can cause 
dysfunction of both reflexes, resulting in gait abnormalities.26  Individuals with 
vestibulopathy must compensate for decreased VOR function or they experience blurred 
vision or oscillopsia (movement of objects in their visual field).  Individuals with 
vestibulopathy must compensate for decreased VSR function or they experience postural 
instability.27  The resultant compensations have the potential to affect gait. 
Role of Vestibular System in Gait 
The vestibular system, along with the visual and peripheral somatosensory 
systems, provides input to the nervous system about the position and movement of the 
body and its parts.  Visual inputs may provide information about direction and speed of 
gait, and lower limb joint and muscle receptors may provide information about direction 
of gait.28  Little is known about the specific role of the vestibular system in gait. 
Kennedy et al investigated the relative contributions of the visual and vestibular 
systems to gait trajectory in subjects without known vestibular pathology.28  They 
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provided binaural galvanic stimulation, which produces a change in walking trajectory 
toward the side of the anode.  When the stimulation was applied with eyes closed, there 
was a larger lateral deviation than when the stimulation was applied with eyes open.  The 
authors concluded that the nervous system weighs visual information more heavily than 
vestibular information in the control of gait trajectory. 
Vestibular Rehabilitation 
A group of patients who commonly receive physical therapy intervention and who 
can have gait dysfunction are those with vestibular disorders.  Numerous studies have 
been conducted to examine the effectiveness of rehabilitation in patients with vestibular 
dysfunction.  These studies have examined the effect of VR on computerized 
posturography,1, 3, 5, 7, 29, 6, 30, 31, 32 subjective complaints of dizziness,3, 7, 33, 9, 34, 35 
clinical balance measures,4, 7, 36, 34, 37 performance of activities of daily living,8, 29 gait 
velocity,9 control of the body’s center of gravity,6, 9 clinical examination,2 and the 
subject’s perceived level of disability.3, 4, 9, 38, 34  The results of these studies indicate 
significant improvement for the majority of patients with vestibular pathology who 
participate in VR. 
Some of the studies compared individualized VR programs with sham treatment, 
non-specific interventions, or no intervention and found VR to produce significantly 
greater improvements in the measures examined.3, 7, 9, 6, 29 
Patten et al examined the strategies used by subjects with vestibular pathology 
that resulted in improved stability after participation in VR.39  They found that after 
participating in a VR program, subjects with bilateral vestibular hypofunction improved 
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their head-trunk coordination resulting in improved sagittal plane head control during 
walking. 
Krebs et al conducted a double-blind, placebo-controlled trial of VR for subjects 
with bilateral vestibular hypofunction.9  They found less self-reported disability and 
decreased double support duration following VR. 
A study conducted by Krebs et al in 2003 investigated the characteristics of 
patients who benefited from VR compared to those who did not.40  The investigators 
determined that in the subjects with vestibulopathy who participated in their study, 60% 
benefited from VR, as evidenced by increased gait speed and decreased double support 
time.  They determined that those subjects who benefited most from rehabilitation were 
those who decreased their vertical head and body center of mass excursion. 
A recent study was the first attempt to investigate the relationships among balance 
impairments, functional performance, and disability in patients with peripheral vestibular 
disorders.41  The subjects in this study were 41 patients with unilateral vestibular 
hypofunction and 44 with bilateral vestibular hypofunction.  Data collected included 
clinical balance measures, a timed walking test, and the Dizziness Handicap Inventory.  
The results indicate that balance impairments and functional performance are closely 
related to disability in patients with bilateral vestibular hypofunction, but not in those 
with unilateral peripheral vestibular hypofunction.  The authors speculate that other 
factors not measured in their study may contribute to disability in patients with unilateral 
peripheral vestibular hypofunction. 
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Gait in Vestibular Dysfunction 
Conrad et al published one of the first research reports of gait in vestibular 
dysfunction.18  They presented a case study of a subject who sustained bilateral vestibular 
loss as a result of bacterial meningitis.  Gait analysis using foot switches and surface 
electromyography revealed the following gait deviations: decreased step length, increased 
period of “flat-foot” contact, increased ratio of double-support to stride period, and 
abnormal gastrocnemius and tibialis anterior muscle activity during stance phase.  Conrad 
et al noted that similar changes in gait occur in subjects without vestibular pathology 
when their stability is threatened.  They felt that in persons without vestibular pathology 
the gait changes represent protective mechanisms to prevent loss of balance resulting in a 
greater expenditure of energy per step. 
Brandt et al noted that subjects with vestibulopathy had smaller deviations from 
the intended progression path at higher speeds than at slower speeds.42  They speculated 
that this could be due to the activation of spinal central pattern generators that may 
suppress vestibular input. 
Ishikawa et al published a series of studies investigating gait in subjects with 
various vestibular pathologies.  The first study involved 14 healthy control subjects and 
31 subjects with vestibular disorders: 21 had lesions of the peripheral apparatus and 10 
had central lesions.10  They used foot switches and surface electromyography (EMG) for 
gait analysis.  The variables analyzed included: time from heel strike to forefoot strike 
(HA-I), time from heel off to forefoot off (HA-II), stance duration, swing duration, and 
double support duration.  The incidence of abnormality was highest in HA-I, followed by 
stance and swing durations, and the occurrence of these abnormalities was greater in the 
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subjects with central lesions compared to persons with peripheral lesions.  The authors 
reported ranges of results for the healthy controls, but reported only incidence of 
abnormality for the subjects with vestibular lesions. 
Ishikawa et al also investigated the gait of subjects with peripheral vestibular 
lesions over time.11  They used the foot switch and surface EMG system to collect gait 
data from 23 patients with peripheral vestibular disorders.  It appears that all subjects had 
unilateral lesions, although this was not stated.  Gait analysis was performed in both the 
acute and recovery stages.  No operational definitions were provided for the terms 
“acute” and “recovery.”  The findings were similar to the previous study: incidence of 
abnormality was highest for HA-I, followed by swing duration, stance duration, and 
double support duration.  They also reported that the abnormal gait variables returned to 
normal ranges when examined at recovery stage.  The authors speculated that increased 
HA-I may be indicative of a balance disorder.   Ishikawa et al reported only incidence of 
abnormality for each gait variable studied and graphically depicted the coefficient of 
variation for several variables. 
Another publication by Ishikawa et al confirmed the presence of gait 
abnormalities in patients with vestibular disorders.12  The subjects included 14 healthy 
adults and 30 patients, 10 with vestibular neuronitis, 10 with large acoustic neuroma, and 
10 with olivo-ponto-cerebellar atrophy.  Gait analysis was carried out using foot switches 
and surface EMG.  In all three groups, the highest occurrence of abnormality was in HA-
I, followed by swing, stance, and double support durations.  This report included 
coefficients of variation for all gait variables measured for all three groups of patients, 
but did not report means or ranges for the variables. 
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A more recent study that examined gait variables in patients with vestibular 
dysfunction was conducted  by Tucker et al.13  The subjects in this study included six 
patients with bilateral vestibular hypofunction and a group of 16 healthy control subjects.  
Instrumentation included a four-camera SELSPOT II system and two Kistler 
piezoelectric force platforms.  The researchers used an 11-segment computer model to 
calculate whole body center of gravity kinematics.  Gait analysis was performed during 
two trials of free speed walking, followed by two trials paced with a metronome at 120 
beats/minute. Subjects with bilateral vestibular hypofunction selected a longer cycle time, 
decreased vertical center of gravity displacement, and increased percentage of double 
support phase during free speed gait.  The authors speculated that this movement strategy 
represented a choice of a more stable gait pattern, and may allow more time for spinal 
cord level corrective loops. 
Pozzo et al investigated control of head position during gait in participants with 
and without  vestibulopathy.43  They examined head position and movement during free 
walking, walking in place, running in place, and hopping.  The gait of subjects with 
vestibulopathy demonstrated decreased stride length, increased base of support, 
decreased speed, and increased stance phase duration compared to subjects without 
vestibulopathy.  The authors speculate that decreased VSR function could lead to these 
gait disturbances.  Other findings of the study were that subjects without vestibulopathy 
were able to maintain their head position within a very small range. Subjects with 
vestibulopathy had a significantly decreased ability to stabilize head position and tended 
to rely on visual landmarks to stabilize gaze.  The authors conclude that subjects 
compensate for decreased VOR function by using vision to stabilize head position. 
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Yamamoto et al investigated the effect of caloric stimulation on gait in subjects 
without vestibulopathy.44  Ear stimulation with cold water causes asymmetric input from 
the right and left vestibular apparatuses, with ipsilateral suppression.  The nervous system 
interprets this input as contralateral head turning which would result in contralateral 
vestibular excitation.  They provided caloric stimulation and asked subjects to walk on a 
treadmill, while body movement data were collected.  Caloric vestibular stimulation 
resulted in significantly increased translation of the head and trunk in the frontal plane. 
Further evidence of vestibular control of medial-lateral balance was reported by 
O’Kane et al45 who collected kinematic and force plate data from subjects with and 
without vestibular hypofunction as they terminated their gait.   The subjects with 
vestibulopathy had significantly slower gait and they had greater difficulty controlling 
lateral stability at gait termination.  Kaya et al also provide support for the role of the 
vestibular system in medial-lateral balance control.46  They reported that subjects with 
vestibular hypofunction had slower gait speed and exhibited increased lateral momentum 
during locomotion. 
Problems with medial-lateral control of the center of mass could affect base of 
support during standing and walking.  The traditional belief that individuals with medial-
lateral postural control deficits demonstrate an increased base of support was expressed 
by Gill-Body,47 who stated that gait changes indicating increased gait stability include a 
reduction in the base of support.  This concept was reinforced by Fried et al,48 who found 
an increased base of support in fall-prone subjects.  Recent evidence about base of 
support in subjects with vestibular pathology does not support the belief that their balance 
difficulties should result in increased base of support.49, 50 
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Seidel et al investigated the base of support in subjects with vestibulopathy, 
cerebellar disorder, and subjects without either pathology.49  They collected kinematic 
data using a video-based motion analysis system.  Base of support was defined as the 
distance between the centers of mass of the left and right feet.  Results indicated no 
significant difference in base of support among subject groups.  Base of support did not 
change with gait speed and was not related to age in these subjects. 
Krebs et al investigated base of support in subjects with vestibular pathology.50  
Base of support was defined in the same manner as Seidel et al.  The investigators 
reported that base of support at heel strike is not different between subjects with 
vestibular dysfunction and those without.  They also found that at their preferred gait 
speed, subjects with vestibular pathology were able to compensate for their instability by 
walking slowly and restricting movement of the center of mass.  At faster speeds, they 
increased their interfoot distance during swing but not at heel strike. 
In summary, gait deviations in subjects with vestibulopathy are likely related to 
decreased or absent VOR and VSR function and the compensation for these deficits.  
Gait deficits include slow gait speed, altered control of center of mass, and altered timing. 
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CHAPTER 3: STUDY 1 – TEST-RETEST RELIABILITY OF THE 
INSTRUMENT 
Introduction 
The purpose of this study was to evaluate the reliability of the investigator’s 
technique for measuring interswitch distances using digital calipers.  This measurement 
was used in the second study, to examine the distances between switches on the surface 
of several GaitMats.  
Method 
Instrumentation 
GaitMat II 
The GaitMat II (GM) system is described in Chapter 1. 
Calipers 
Electronic calipers which have a digital display were used to indicate the distance 
between the two caliper points, to the nearest 0.01 millimeter. (Digi Kanon, EMA-15, 
Nakamura Mfg. Co. Ltd.) 
Operational Definitions 
Refer to Figure 1 when reviewing the following operational definitions: 
Transverse Panel Intersection:  The intersection where one panel meets an 
adjacent panel; this intersection is oriented perpendicular to the direction of progression 
along the walkway.  The distance between switches on either side of this intersection was 
measured. 
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Figure 1.— Types of interswitch distances.  Five different types of interswitch distances 
were measured: regular longitudinal, transverse longitudinal, sheet intersection, 
longitudinal panel intersection, and transverse panel intersection.  See text for operational 
definitions. 
 
 
 
Longitudinal Panel Intersection:  The intersection where a panel can fold in half; 
this intersection is oriented parallel to the direction of progression along the walkway.  
The distance between switches on either side of this intersection was measured. 
Sheet Intersection:  The intersection where one sheet of switches meets an 
adjacent sheet of switches; this intersection is oriented perpendicular to the direction of 
progression along the walkway.  The distance between switches on either side of this 
intersection was measured; these switches are parallel to the walkway. 
Regular Longitudinal:  The longitudinal distance between two switches that were 
not located along a panel or sheet intersection. 
Regular Transverse:  The transverse distance between two switches that were not 
located along a panel or sheet intersection.  
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Procedure 
To evaluate the interswitch distance with the electronic caliper, a test-retest 
reliability study was performed.  Ten different pairs of switches were randomly selected 
along the GaitMat and marked.  These comprised a sample of all possible interswitch 
distance types: longitudinal panel intersection, transverse panel intersection, sheet 
intersection, regular longitudinal and regular transverse.  According to the manufacturer, 
all of these distances should be 15 mm.51  The distances between the switch pairs 
numbered one through ten were measured sequentially.  The caliper was adjusted to align 
the points with the estimated centers of each of the two switches.  This sequence of 
measurements was repeated for a total of five repeated measurements of ten different 
interswitch distances.  The digital output was covered during the measurement, in order 
to blind the investigator to the numerical value.  The caliper was returned to a zero 
distance between the caliper pointers after the value was noted and before the next 
measurement was made.  
Data Analysis 
The test-retest reliability was examined using the intraclass correlation coefficient 
(ICC), model 3, form 1.  The ICC is a reliability coefficient calculated from variance 
estimates obtained through an analysis of variance.   It reflects both degree of 
correspondence and agreement among ratings.  Model 3 was chosen, because it is 
calculated from a repeated measures analysis of variance.  Form 1 was chosen because it 
is appropriate when the single rater is the only rater of interest.20  Because the 
investigator had no previous experience using calipers for measurement, it is reasonable 
to assume that some learning was required to achieve acceptable reliability with the 
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technique.  Discounting the first two sequences of measurements between each pair of 
switches took the learning effect into account.  Therefore, the first two sequences were 
not included in the analysis, and only the last three sequences were used to calculate the 
ICC. 
Results 
The interswitch distance measurements follow: 
 
Table 1. — Repeated Interswitch Distance Measures (mm) 
 
Switch 
Pair 
Measure
1 
Measure
2 
Measure
3 
Measure
4 
Measure 
5 
1 13.81 14.05 13.98 14.22 14.22 
2 14.47 15.01 14.25 14.35 14.25 
3 15.14 16.24 16.71 16.39 16.42 
4 14.96 14.20 14.57 14.51 14.70 
5 14.37 14.42 14.84 14.50 14.35 
6 18.93 14.34 18.31 17.22 19.21 
7 14.15 14.40 15.98 16.30 15.34 
8 16.63 16.64 16.66 15.98 16.76 
9 14.71 14.93 14.51 14.53 15.08 
10 16.38 17.19 15.91 16.82 16.33 
 
 
 
If all five measures were included in the ICC (3,1) calculation, the value obtained 
was only 0.68.  However, if the first two measures were not included in the calculation, 
an excellent ICC value of 0.90 was obtained.  This indicates that the measure of 
interswitch distance made by this rater with this electronic caliper can be considered 
reliable once initial learning had occurred. 
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CHAPTER 4: STUDY 2 – VARIATION OF INTERSWITCH DISTANCES 
Introduction 
Because the spatiotemporal gait calculations made by the GM are based on an 
assumption of even spacing of the switches at 15 mm on the surface of the mat, variation 
in interswitch distance has the potential to affect the accuracy of the data obtained with 
the GM.  The purpose of this study was to examine the placement of switches on the 
surfaces of several GaitMats.  
Method 
Procedure 
Three GM systems were compared with regard to switch placement.  These mats 
were located at Arcadia University (Arcadia), Temple University School of Podiatric 
Medicine (TUSPM), and University of the Sciences in Philadelphia (USP). 
A number of different interswitch distances were measured for each of the three 
mats.  These comprised a sample of all possible interswitch distance types: longitudinal 
panel intersection, transverse panel intersection, sheet intersection, regular longitudinal 
and regular transverse.  The investigator used the electronic caliper technique evaluated 
for reliability in the first pilot study to obtain these measurements.  
Data Analysis 
Variances for the interswitch distances for the three GMs were not equal.  
Therefore, the interswitch distances for the three GMs were compared using a Kruskal-
Wallis one-way analysis of variance by ranks.52  A significance level of 0.05 was chosen. 
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The interswitch distances for the different switch types were analyzed using a 
Friedman two-way analysis of variance by ranks.52  A significance level of 0.05 was 
chosen. 
To examine consistency of switch placement, and therefore reliability, intraclass 
correlation coefficients were calculated for each switch type.  The ICC values were used 
to calculate the standard error of measurement (SEM) for each switch type.  The standard 
error of measurement is an estimate of how much a score is likely to vary with repeated 
measurements.53  It is calculated using the following formula: 
 
(1) 
r1SEM −=σ  
 
σ = standard deviation 
r = reliability coefficient; in this case, the intraclass  
correlation coefficient 
 
 
 
The standard error of measurement is the standard deviation of the population of 
all possible measurement errors, and can be used as an estimate of reliability.  The SEM 
can be interpreted according to the properties of the normal curve.  There is a 68% 
chance that the true measurement lies within ± 1 SEM of the group mean and a 95% 
chance that the true measurement lies within ± 2 SEM of the group mean.  In this case, 
the SEM reflects the range of scores that can be expected on repeated testing.52   
Results 
All interswitch distances for each mat and switch type can be found in Appendix 
A (page 80).  Table 2 summarizes descriptive statistics for interswitch distances. 
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Table 2. — Interswitch Distance Means and Standard Deviations (mm) 
 
Switch Type 
 
GM 
Location 
Longitudinal 
Panel 
Intersection 
Transverse 
Panel 
Intersection 
Sheet 
Intersection 
Longitudinal 
Regular 
Transverse 
Regular 
 Mean (SD) 
N 
Mean 
(SD) 
N 
Mean 
(SD) 
N 
Mean 
(SD) 
N 
Mean 
(SD) 
N 
TUSPM 17.09  
(0.58) 
15 
20.50 
(1.23) 
15 
15.97 
(.68) 
15 
14.19 
(.47) 
15 
14.82 
(.36) 
15 
Arcadia 18.15  
(0.96) 
15 
17.45  
(0.58) 
15 
16.79  
(.52) 
15 
15.06 
(.35) 
15 
14.75  
(.25) 
15 
USP 18.33  
(0.61) 
15 
19.05  
(0.59) 
15 
15.84  
(.61) 
15 
14.98 
(.35) 
15 
14.93 
(.39) 
15 
      
Overall 17.91  
(0.93) 
45 
19.00 
(1.51) 
45 
16.20 
(0.73) 
45 
14.74  
(0.56) 
45 
14.83  
(0.34) 
45 
 
 
Table 3 contains a summary of the Kruskal-Wallis one-way analysis of variance, 
comparing the three GMs.  The Kruskal-Wallis one-way analysis of variance uses the H 
statistic, calculated using the following equation:52 
 
(2) 
)1N(3
n
R
)1N(N
12H
2
i +−+= ∑  
 
N = number of cases in all samples combined 
n = number of individual samples 
Ri = sum of ranks for sample i 
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The calculated H value was 0.32, which is less than the critical H value of 5.78; 
therefore, the null hypothesis was not rejected.  There was no significant difference in 
interswitch distance among the three GMs. 
 
Table 3. — Summary of Kruskal-Wallis One-Way Analysis of Variance by Ranks: 
Effect of Mat on Interswitch Distance 
 
TUSPM Rank Arcadia Rank USP Rank 
Longitudinal Panel Intersection 17.09 10 18.15 12 18.33 13 
Transverse Panel Intersection 20.50 15 17.45 11 19.05 14 
Sheet Intersection 15.97 7 16.79 9 15.84 8 
Longitudinal Regular 14.19 1 15.06 6 14.98 5 
Transverse Regular 14.82 3 14.75 2 14.93 4 
R1 35 R2 41 R3 44 
R12 1225 R22 1681 R32 1936 
df=2 
χ2=5.78 
Hcalc = 0.32 
 
 
 
Table 4 contains a summary of the Friedman two-way analysis of variance by 
ranks, comparing the interswitch distances for different switch types.  The Friedman two-
way analysis of variance uses the χ2r statistic calculated using the following equation: 
 
(3) 
)1k(n3R
)1k(nk
12 2
i
2
r +−∑+=χ  
 
n = Number of subjects (mats) 
k = Number of treatment conditions (switch types) 
Ri = Sum of ranks for each treatment condition 
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The calculated χ2r value was 19.93, greater than the critical χ2r value of 9.49.  
Because the calculated χ2r was greater than the critical value, the null hypothesis was 
rejected, indicating that there was a significant difference between switch types. 
 
 
Table 4. — Summary of Friedman Two-Way Analysis of Variance by Ranks: Effect 
of Switch Type on Interswitch Distance 
 
Switch 
Type 
Mat 
Location   
Longitudina
l 
Panel 
Intersection 
R
ank 
Transverse
Panel 
Intersectio
n 
R
ank 
Sheet 
Intersection
R
ank 
Longitudina
l 
Regular 
R
ank 
Transverse
Regular 
R
ank 
TUSP
M 
17.09 4 20.50 5 15.97 3 14.19 1 14.82 2 
Arcadia 18.15 5 17.45 4 16.79 3 15.06 2 14.75 1 
USP 18.33 4 19.05 5 15.84 3 14.98 2 14.93 1 
 R1 13 R2 14 R3 9 R4 5 R5 4 
 R12 169 R22 196 R32 81 R42 25 R52 16 
df=2 
χ2 = 9.49 
Xr2 calc = 19.93 
 
 
 
To identify the source of the significant differences, multiple comparisons of 
pairwise differences were calculated using the formula52: 
(4) 
6
)1k(nkzRR 21
+≥−  
 
R1  = Rank total for condition 1 
R2  =  Rank total for condition 2 
n  = Number of subjects 
k  = Number of treatment conditions 
z  = Area under normal curve, based on total # of 
comparisons and desired level of significance 
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This formula calculates the minimum significant difference (MSD) between each 
pair of conditions.  The MSD is compared with the actual difference between the mean 
ranks for the pair of conditions.  If the absolute difference is greater than the MSD, it is 
considered significant.52 
Table 5 contains the results of the pairwise comparisons.  Significant differences 
were found between transverse panel intersections and longitudinal regular, and between 
transverse panel intersections and transverse regular interswitch distances. 
 
 
Table 5. — Pairwise Comparisons of Differences Between Ranks 
 
Pairs MSD 
Longitudinal Panel Intersection 
Transverse Panel Intersection 1 
Longitudinal Panel Intersection 
Sheet Intersection 4 
Longitudinal Panel Intersection 
Longitudinal Regular 9 
Longitudinal Panel Intersection 
Transverse Regular 9 
Transverse Panel Intersection 
Sheet Intersection 5 
Transverse Panel Intersection 
Longitudinal Regular 10 * 
Transverse Panel Intersection 
Transverse Regular 10 * 
Sheet Intersection 
Longitudinal Regular 5 
Sheet Intersection 
Transverse Regular 5 
Longitudinal Regular 
Transverse Regular 1 
* p < 0.05
MSD = Minimum Significant Difference
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Table 6 contains the intraclass correlation coefficients for the interswitch distance 
types.  Values ranged from 0.00035 to 0.17500.  The ICC values were used to calculate 
standard error of measurement (SEM) for each switch type for each mat.  Table 7 
contains the SEM values. 
 
 
Table 6. — Intraclass Correlation Coefficient Values for Switch Types 
 
Switch Type ICC 
Longitudinal Panel Intersection 0.15414 
Transverse Panel Intersection 0.00035 
Sheet Intersection 0.17500 
Longitudinal Regular 0.00264 
Transverse Regular 0.05175 
 
 
 
Table 7. — Standard Errors of Measurement and Means for Interswitch Distances, 
mm 
 
Switch Type  TUSPM Arcadia USP 
Longitudinal Regular Mean 14.19 15.06 14.98 
 SEM 0.4528 0.3501 0.3499 
Transverse Regular Mean 14.82 14.75 14.93 
 SEM 0.3515 0.2334 0.3619 
Sheet Intersection Mean 15.97 16.79 15.84 
 SEM 0.5702 0.4380 0.4993 
Longitudinal Panel Intersection Mean 17.09 18.15 18.33 
 SEM 0.4542 0.7588 0.4876 
Transverse Panel Intersection Mean 20.50 17.45 19.05 
 SEM 1.3593 0.5957 0.6267 
 
 
 
Discussion 
The first study demonstrated that the electronic calipers can be used reliably to 
measure the distance between GM switches.  The second study demonstrated statistically 
significant differences between different interswitch distance types, but no significant 
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differences were found among the three GMs evaluated, with respect to switch 
placement.  The significant differences were among different switch types, with 
transverse panel intersection distances ( X  = 18.84 mm) significantly different from 
longitudinal regular distances ( X = 14.77 mm) and from transverse regular distances ( X  
= 14.81 mm). 
An issue of concern is the difference between the measured interswitch distances 
and the assumed interswitch distance of 15 mm.  This issue is potentially important 
because according to the developer of the GM software, all distance calculations are 
based on the assumption that all switches on the GM surface are evenly spaced at 15 mm 
apart.51  If the switches are actually spaced at a greater or lesser distance, the calculated 
distance values would be less or greater than the actual distance values, which would 
result in a systematic measurement error.  Table 8 includes the mean differences (in mm) 
between the measured interswitch distances and the assumed value of 15 mm, and the 
percent error for each type of measure. 
Error Analysis 
Error can be analyzed either by examining percent error or SEM values.  A review 
of the percent errors shows the highest error is in the transverse panel intersection (15.3% 
to 35%), followed by longitudinal panel intersection (13.9% to 22.2%).  The largest SEM 
values were also for transverse panel intersection and longitudinal panel intersection, 
indicating that these are also the most variable values.  Gait variables are calculated by 
the computer from the GM switch closure data.  The transverse panel intersection could 
potentially affect the calculation of a number of gait variables: step length, stride length, 
and average velocity. 
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Table 8. — Mean Differences and Percent Error Between Interswitch Distances and 
the Assumed Value of 15 mm Used in Distance Calculations by GM Software 
 
Switch Type  
GM 
Location 
Longitudinal 
Panel 
Intersection 
Transverse 
Panel 
Intersection 
Sheet 
Intersection 
Regular 
Longitudinal 
Regular 
Transverse 
 Diff 
(mm) 
Error Diff 
(mm)
Error Diff 
(mm)
Error Diff 
(mm) 
Error Diff 
(mm)
Error
TUSPM 2.09 13.9% 5.25 35 % 0.61 4.1% -0.80 5.3% -0.25 1.7%
Arcadia 3.15 21% 2.29 15.3% 1.37 9.1% 0.06 0.4% -0.20 1.3%
USP 3.33 22.2% 4.26 28.4% 1.09 7.3% -0.12 0.8% -0.14 0.9%
 
 
 
The following diagram will be used to illustrate the potential effect of these errors 
on gait variable calculation: 
 
 
 
 
 
 
 
 
 
 
Figure 2. — Sample walk across GaitMat 
 
 
 
Example: Step Length 
Step length is defined as the distance longitudinally along the GM from the first 
switch closure of one footprint to the first switch closure of the next footprint.  The 
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procedure that the system uses is to determine the number of switches between the first 
switch closure of the first footprint and the first switch closure of the next footprint.  The 
assumption is then made that the distance between each of the intervening switches is 15 
mm and the step length distance is calculated by multiplying the number of switches by 
15 mm. Data collected from healthy young adults using the GM are found in Table 9.  
Normal step lengths were found to be approximately 65 cm long.  In the diagram above, 
most steps would cross only one transverse panel intersection.  The interswitch distance 
across the transverse panel intersection could be as much as 5.25 mm larger than the 
assumed value of 15 mm.  In addition, a step that is 65 cm long would cross 43 regular 
longitudinal interswitch intervals.  Based on percent error, each of these distances could 
be as much as 0.80 mm smaller than the assumed value of 15 mm, for a total of 34.4 mm 
difference.  The total of these two differences could mean that the calculated length for 
this step could be 29.2 mm larger than the actual step length, a 4.5% difference. Under 
the normality assumption, there is a 95% chance that the transverse panel intersection is 
within 1.7 mm of the actual value.  In addition, there is a 95% chance that the 43 regular 
longitudinal interswitch intervals are within 0.77 mm of the actual values, for a worst 
case total of 34.4 mm error, or 5.2%. 
Example: Stride Length 
Stride length is defined as the distance longitudinally along the GM from the first 
switch closure of a footprint to the first switch closure of the next footprint made by the 
same foot.  The stride length calculation is made by multiplying the number of 
intervening switches by the assumed interswitch distance of 15 mm.  Data collected from 
healthy young adults using the GM yielded an approximate normal stride length of 130 
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cm.  In the diagram above, each 130 cm stride would cross only one transverse panel 
intersection and 86 regular longitudinal interswitch intervals.  Based on percent error, the 
combination of these two differences could result in a calculated stride length that is 63.6 
mm larger than the actual stride length.  This amounts to a 4.9% potential difference 
between the calculated and actual stride lengths.  Based on the normal model, the worst 
case total error is 67.1 mm or 5.2%. 
Example: Average Speed 
Average speed is defined as the distance between the first switch closures of the 
first and last footprints divided by the time between the earliest switch closures of the 
first and last footprints.  In the diagram above, five steps are represented.  Based on the 
data collected from young adults, the total distance for these five steps would be 
approximately 325 cm.  Three transverse panel intersections are crossed.  Based on 
percent error, this could result in a possible total distance error of 15.75 mm.  Five steps 
would cross approximately 216 regular longitudinal interswitch intervals, for a total error 
of 157 mm.  The combined error from these three sources could lead to a calculated 
distance that is 4.8% greater than the actual distance, making the calculated velocity 
greater than the actual velocity.  Based on the normal model, the worst case total error for 
distance would be 205 mm, or 6.3%. 
These examples illustrate the potential impact created by the difference between 
actual and assumed transverse panel intersection and regular longitudinal distances on the 
gait variables of step length, stride length, and average velocity.  However, the results 
may not be the same for the difference in the longitudinal panel intersection distance. 
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Example: Support Base 
The longitudinal panel intersection error could potentially affect the calculation of 
only one gait variable, support base.  Support base is determined by the GM software as 
the distance between the most medially located switch closure for one footprint and the 
most medially located switch closure for the next footprint.  Data collected from healthy 
young adults using the GM yielded an approximate normal support base of 36 cm.  With 
this support base, each step spans one longitudinal panel intersection and 23 regular 
transverse intervals.  The longitudinal panel intersection interswitch distance can be as 
much as 3.33 mm greater than the assumed value of 15 mm.  Each of the 23 regular 
transverse intervals can be as much as 0.25 mm smaller than the actual distance.  The 
combination of these two sources of error could amount to as much as 2.4 mm difference 
between the calculated support base and actual support base, or 0.6%.  The SEM for 
longitudinal panel intersection was 7.8 mm, and for regular transverse intervals was 0.63 
mm, resulting in 6.2% error. 
To evaluate the practical significance of the measured differences in interswitch 
distances, the variation that occurs during normal adult gait was examined.  
Normative gait data was obtained from eight adults with no known pathology that 
would affect walking ability.  Each subject walked across the GM 20 times.  Data were 
collected and means and standard deviations calculated for each gait variable.  Table 9 
contains a summary of the means and standard deviations of the gait variables for 
subjects without vestibular pathology.  For the distance measures (step length, stride 
length, and support base), standard deviations ranged from 2.9 cm to 5.2 cm.  The 
difference between the mean interswitch distance for transverse panel intersection and 
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longitudinal regular switch types was 4.07 mm.  The largest difference from the assumed 
15 mm interswitch distance was 5.25 mm.  Therefore, the variation in the distance 
variables of normal human gait, ranging from 2.9 to 5.2 cm, is much greater than the 
error created by switch placement on the GM surface.  Additionally, the 2 SEM values 
for interswitch distances ranged from 0.02334 cm to 0.27187 cm, far less than the 2.9 to 
5.2 cm variation in normal human gait.  Because of this, the switch placement error is not 
practically or clinically significant. 
 
 
Table 9. — Summary of Normal Gait Variables and Comparison to Interswitch 
Distance SEM 
 
 Mean SD Interswitch DistanceSEM 
Left Step Length (cm) 63.6 3.8 0.0344 
Right Step Length (cm) 64.0 3.3 0.0344 
Left Stride Length (cm) 128 5.2 0.0671 
Right Stride Length (cm) 128 4.9 0.0671 
Left Support Base (cm) 41.8 3.1 0.0223 
Right Support Base (cm) 30.6 2.9 0.0223 
 
 
 
Summary 
The results of these three studies indicate that electronic calipers can reliably 
measure the distances between switches on the surface of the GM.  The results also 
indicate that the three systems examined are similar in manufacture with regard to 
interswitch distances. (See Table 4)  A statistically significant difference was found 
between regular interswitch distances and transverse panel intersection interswitch 
distances.  When compared to the variation in distance variables of gait in a sample of 
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healthy adults, however, these differences are not practically or clinically significant. 
(See Table 9)  
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CHAPTER 5: STUDY 4 – HA-I DETERMINATION 
Introduction 
A study was conducted to determine a technique for reliably determining the gait 
variable HA-I from GM data.  HA-I is the time from heel strike to forefoot strike, which 
was found by Ishikawa et al to be abnormally increased in subjects with vestibular 
dysfunction,10 and which will be examined in the second research study included in this 
proposal.  The researchers in the original study that evaluated HA-I used heel and 
forefoot switches to collect gait data. 
Method 
To develop a method for obtaining this value from GM data, the switch closure 
data were examined from a total of 80 steps produced by 8 subjects without pathology.  
The GM switch closure data displays the sampling interval in which each switch was 
found to be closed by the computer.  An example of switch closure data displayed by the 
GM is found in Figure 3. 
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Direction of 
Progression 
 
Figure 3. — Sample switch closure data from GaitMat.  This sample represents one 
footstep, with the heel at the bottom of the figure and the toe area at the top of the figure.  
A value of “-1” indicates that the switch occupying that position on the surface of the GM 
was open when sampled.  A value other than -1 indicates the number of the sampling 
interval during which the switch was first found to be closed. 
 
 
 
To determine HA-I, each footstep was divided into hindfoot and forefoot sections, 
and the earliest switch closure for each section was identified.  Figure 4 illustrates switch 
closure events that were used to determine HA-I.  Examination of numerous footsteps 
from normal individuals revealed the earliest hindfoot switch closure generally occurred 
in the first or second row and the earliest forefoot switch closure occurred between 70% 
and 75% of the total foot length.  Based on these observations, the method used to 
determine HA-I from GM data involved first identifying the earliest switch closure in the 
first row of switches and the earliest switch closure in the row located 70% to 75% along 
the length of the foot.  The difference between these two values represents the number of 
sampling intervals that elapsed between hindfoot switch closure and forefoot switch 
closure.  This value was multiplied by the sampling interval (0.005 s) to obtain the time 
between hindfoot and forefoot contact (HA-I). 
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Figure 4. — Determination of HA-I.  In this right footstep, the lower circle indicates the 
hindfoot section and the upper circle indicates the forefoot section.  The first hindfoot 
switch closure (lower arrow) was found during sampling interval #692, located in row 1.  
The first forefoot switch closure (upper arrow) was found during sampling interval #729, 
located in row 12.  The footstep is 16 rows long, and the first forefoot switch closure is 
located at 75% of the footstep length.  Therefore, for this footstep, 37 sampling intervals 
elapsed between hindfoot and forefoot switch closures, or (37) (.005) = 0.185 seconds. 
 
 
Data Analysis 
Since this technique was used to determine HA-I in a subsequent study, 
investigation of its reliability was essential.  The reliability of the technique to determine 
HA-I from GM data were examined by determining HA-I for three different subjects 
without pathology and repeating the procedure a second time.  The first and second HA-I 
values were compared using the intraclass correlation coefficient (ICC), model 2, form 1.  
Standard error of measurement was calculated for each of the three subjects. 
Results 
ICC values for the three subjects were 0.830, 0.713, and 0.840, indicating 
moderate to good test-retest reliability.  Standard errors of measurement were 0.0153 s, 
0.0208 s, and 0.0318 s.  These findings indicate that the technique used in this study to 
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determine time from heel contact to forefoot contact (HA-I) has acceptable test-retest 
reliability. 
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CHAPTER 6: STUDY 5 - GM ACCURACY, RELIABILITY, AND VALIDITY 
Introduction 
The research question to be answered by this study was: Does the GaitMat II 
accurately measure switch closure events with respect to distance and time?  Therefore, a 
known repetitive signal was presented simultaneously to the GM and a sophisticated 
motion analysis system and the results were compared.  This study was designed to 
examine the GM’s concurrent validity. 
Method 
Instrumentation 
GaitMat II 
The GaitMat II system was used in this research study.  See Chapter 1 for a 
description of the system. 
Vicon 370 
The Vicon 370 motion analysis system is a five-camera system that is able to 
localize reflective markers in a three-dimensional coordinate system within 1.5 mm error.  
The cameras have 300,000 pixels and sample at a rate of 120 Hz, one frame every 8.33 
msec.  It is an expensive system that is permanently located in a gait analysis laboratory.  
Because of its high level of accuracy and reliability, it is considered a “gold standard” for 
motion analysis. 
Weight 
A cylindrical weight, 16 cm in diameter and 16 cm in height, certified by the 
Philadelphia Bureau of Weights and Measures (49 lb.), was used in this study to produce 
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known distance and timing events.  A reflective marker was used to determine distance 
and timing measures associated with the weight’s movement. 
Membrane Switch 
A membrane switch was attached to the surface of the GM directly over a GM 
surface switch.  The signal was fed into an analog channel on the Vicon system to 
synchronize the outputs from the GM and Vicon systems.  
Procedure 
The GaitMat was located in the field of view of the Vicon system’s cameras.  A 
reflective marker was placed on the flat surface of the cylindrical weight, near the edge. 
 
 
 
 
 
 
 
Figure 5. — Reflective marker on cylindrical weight.  As the weight rolled, the point 
marked with the reflective marker traveled in a regular repetitive pattern. 
 
 
 
An adjustable height ramp was used to position the weight so that when a gate 
was opened, the weight rolled down the ramp and along the surface of the GM.  As the 
weight rolled along the GM, the marker followed a regular path, producing known 
distance and timing events. 
 
 
 
 
= Reflective 
 Marker 
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Figure 6. — Adjustable height ramp.  Released cylindrical weight so it rolled across the 
GM within the field of view of the Vicon motion analysis system. 
 
 
 
In order to compare specific switch closure events between the GM and Vicon, it 
was necessary to identify one switch closure on the GM and the corresponding marker 
orientation from the Vicon data.  To do this, a membrane switch was placed over a GM 
switch in the path of the rolling weight.  The analog signal from the membrane switch 
was fed into a Vicon channel.  When the weight rolled over the superimposed membrane 
and GM switches, it simultaneously closed both of them, creating a reference point for 
both the GM and Vicon systems. 
The vertical location of the marker at the time of membrane switch closure was 
considered the reference point.  The time and vertical location of successive reference 
points was determined from the Vicon data.  The time between successive reference 
points and horizontal distance between successive reference points were compared with 
those obtained by the GM.   
The time between each pair of successive reference points as measured by the 
GM was determined in the following manner.  The switch row located nearest to the 
reference point as identified by the Vicon was identified in the GM switch closure data.  
GATE 
WEIGHT 
Gait Mat 
RAMP 
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The sampling number for the row was identified.  Because the computer sampled the GM 
at an interval of 8 msec, the difference between successive sample numbers was 
multiplied by 0.008 to obtain time between reference points. 
To determine the distance between each pair of successive reference points as 
measured by the GM, the row was identified in the GM switch closure data that contained 
the sample representing the time interval between reference points.  Because the switches 
on the surface of the GM are assumed to be spaced 15 mm apart, the number of rows 
between successive reference points was multiplied by 15 mm to obtain distance between 
reference points. 
Both Vicon and GM data were collected during four trials of the weight rolling 
across the GM. 
Data Analysis 
An intraclass correlation coefficient (2,1) was calculated between the Vicon and 
GM values for distance and time. 
Results 
The Vicon and GM time values, the differences between the two, and the mean 
difference are included in Table 10.  Differences in repeated measures for the Vicon 
represent the combined effects of the 1.5 mm distance resolution or 8.33 msec sampling 
rate and random error. 
The distance values, differences, and mean difference are included in Table 11.  
The ICC for distance is 0.2413, and for time is 0.9942. 
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Table 10. — Vicon and GM Time Values 
 
Test Revolution 
Time per revolution: 
Vicon 
(s) 
Time per revolution: 
GM 
(s) 
Vicon-GM 
Difference  
(s) 
1 1 0.358 0.360 0.002 
 2 0.358 0.360 0.002 
 3 0.367 0.360 0.007 
2 1 0.358 0.360 0.002 
 2 0.358 0.360 0.002 
 3 0.367 0.360 0.007 
3 1 0.408 0.408 0.000 
 2 0.417 0.416 0.001 
 3 0.425 0.424 0.001 
4 1 0.408 0.408 0.000 
 2 0.408 0.408 0.000 
 3 0.425 0.424 0.001 
Mean Difference 0.001 s 
 
 
 
Table 11. — Vicon and GM Distance Values 
 
Test Revolution 
Distance per revolution: 
Vicon 
(mm) 
Distance per 
revolution: GM 
(mm) 
Vicon-GM 
Difference 
(mm) 
1 1 485.974 480 5.974 
 2 477.799 465 12.799 
 3 479.635 465 14.635 
2 1 487.976 480 7.976 
 2 476.965 465 11.965 
 3 479.801 465 14.801 
3 1 485.140 480 5.140 
 2 482.137 465 17.137 
 3 479.634 465 14.634 
4 1 485.641 480 5.641 
 2 476.965 465 11.965 
 3 482.470 465 17.470 
Mean Difference 11.7 mm 
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Discussion 
Distance Measures 
The results are consistent with the resolution provided by the GM.  Because of its 
construction, the GM distance resolution is significantly less than that provided by the 
Vicon.  GM switches are spaced 1.5 cm apart on the surface of the GM, whereas the 
Vicon’s spatial resolution is approximately 1.5 mm.  The ICC of 0.24 for distance 
indicates poor to moderate reliability.52 
Although the difference between the distance measures taken by the Vicon and 
GM is statistically large, these differences are not necessarily clinically meaningful, 
depending on the measure being examined.  The mean difference between the Vicon and 
GM measures is 1.17 cm.  As noted in the “Discussion” section for  Study 2, an error of 
1.17 cm would have little clinical significance in adults for distance measures such as 
step length (mean = 65 cm) or stride length (mean = 130 cm).  However, for support 
base, which can be 8 cm in a healthy adult, an error of 1.17 cm could represent a 
clinically significant error of 14.6%. 
Time Measures 
The GM sampled at a frequency of 0.008 second and therefore showed excellent 
agreement with the Vicon system that sampled the data at a similar rate.  The ICC of 0.99 
for time is considered to indicate good reliability.52  Measurements of timed gait variables 
such as double support time and HA-I would be highly reliable and valid. 
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CHAPTER 7: STUDY 6 – GM VALIDITY 
Introduction 
The research questions to be answered by this study were: 1.) Are there changes 
in gait variables as measured with the GaitMat II in adults with unilateral vestibular 
hypofunction (UVH) after VR?, 2.) Can gait variables, as measured with the GaitMat II, 
predict whether or not an individual has UVH?, and 3.) What is the relationship between 
the changes in gait variables as measured with the GaitMat II and other clinical measures 
in adults with UVH after VR? 
Method 
Instrumentation 
GaitMat II 
The GaitMat II system was used in this research study.  See Chapter 1 for a 
description of the system. 
Dizziness Handicap Inventory 
The Dizziness Handicap Inventory (DHI) is a questionnaire that measures self-
perceived disability as a result of vestibular dysfunction. (Appendix B, page 82)  Scores 
can range from 0 to 100, where 0 indicates no disability and 100 indicates maximum 
disability.  Items are divided into three domains: functional, emotional, and physical.  
Good test-retest reliability has been reported for overall score and for each of the 
individual domain scores.54 
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EquiTest 
The EquiTest is a computerized posturography system that allows the examiner to 
vary sensory inputs and objectively measure postural motor responses. (version 5.08, 
NeuroCom International, Inc., Clackamas, Oregon)  The output is an indication of the 
degree of postural sway under varying sensory conditions, including eyes open, eyes 
closed, with accurate somatosensory cues, and with inaccurate somatosensory cues.  
Sample test results are found in Appendix C, page 84. 
Subjects 
Eleven subjects were recruited from patients diagnosed with unilateral vestibular 
hypofunction (UVH) who were receiving medical care at the Balance Center at Mercy 
Health System in Darby, Pennsylvania.  The study was approved by the Internal Review 
Boards of Mercy Health System, Drexel University, and College Misericordia.  When the 
physician determined that a patient had a diagnosis of UVH, the study was explained to 
the patient and he or she was requested to participate in the study.  A group of persons 
with no history of vestibular dysfunction was recruited from the general population.  
Informed consent was obtained from subjects in both groups.  The volunteers were 
matched to the subjects with UVH for age, gender, height, and weight.  Ranges allowed 
for matching were: age, ± 5 years; height, ± 3 inches; and weight, ± 10% of body weight.  
Demographic information about both groups is included in Table 12.  Medical 
information about subjects in the UVH group is included in Appendix D, page 85. 
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Table 12. — Subject Demographic Information 
 
UVH 
Subject 
# 
Age Gender Height Weight  
Subject 
Without 
Pathology 
# 
Age Gender Height Weight
1 52 M 5’8” 150 1 47 M 5’8” 160 
2 64 M 5’6” 160 2 59 M 5’7” 159 
3 57 M 6’2” 240 3 55 M 6’0” 220 
4 45 M 6’2” 245 4 43 M 6’2” 230 
5 52 M 5’8” 140 5 53 M 5’8” 140 
6 53 M 6’0” 250 6 51 M 6’0” 275 
7 54 M 5’9” 164 7 51 M 5’10” 180 
8 70 M 5’9” 210 8 77 M 5’6” 163 
9 73 M 5’8” 198 9 76 M 5’8” 200 
10 70 F 5’1” 162 10 67 F 5’2” 157 
11 43 M 5’6” 149 11 46 M 5’6” 148 
 
 
 
Inclusion Criteria 
For the subjects with UVH, inclusion criteria included a diagnosis of unilateral 
uncompensated vestibular hypofunction, as evidenced by at least two of the following: 
• At least one clinical sign indicating vestibular asymmetry: spontaneous 
nystagmus, post head-shaking nystagmus,55 rotation > 30° on Fukuda’s 
Stepping Test,56 or positive head thrust maneuver57 
• At least one objective measure indicating UVH: abnormal 
electronystagmography, abnormal rotation testing (decreased VOR gain, 
asymmetry, abnormal phase)58 
• Asymmetrical sensorineural hearing loss 
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Exclusion Criteria 
Exclusion criteria for subjects in both the UVH group and subjects without 
vestibular pathology included inability to follow two-step commands, central or 
peripheral nervous system disorder affecting sensation or motor control, age under 18 
years, and previous VR. 
Procedure: UVH Group 
Informed consent was obtained from each subject in the UVH group once he or 
she had been diagnosed with UVH and had consented to participate in the study, and 
before he or she began participation in VR.  See Appendix E (page 86) for the consent 
form for subjects with UVH.  The subject completed the Dizziness Handicap Inventory 
and was examined by the physical therapist.  The physical therapy examination included 
clinical examination, computerized posturography testing, and GM gait analysis.  
Subjects did not wear shoes during gait analysis.  Gait analysis was conducted, with the 
therapist guarding the subject as needed, while the subject walked across the length of the 
gait mat, four times under each of three conditions.  Rests were required between walks 
and between conditions.  The three conditions were: self-selected speed (SSS), fast speed 
(FS), and walking with head turning (HT). 
The patient participated in a VR program consisting of one clinic visit per week, 
with home exercises performed daily.  The interventions and home exercises were based 
on standard VR procedures,59 and were aimed at facilitating nervous system adaptation.  
They were chosen by the physical therapist, determined individually according to each 
patient’s impairments, functional limitations, and disabilities.  Activities were progressed 
by the physical therapist as indicated by improvement in the patient’s impairments, 
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functional limitations, and disabilities.  On the patient’s last physical therapy visit, the 
data collection that had been performed at the onset of VR was repeated.  
Procedure:  Group Without Vestibular Pathology 
Informed consent was obtained from the subjects without known vestibular 
pathology prior to participation in the study.  See Appendix F (page 90) for the consent 
form for subjects without vestibular pathology.  GM gait analysis was performed in the 
same manner as that used with the subjects with UVH.  Computerized posturography and 
the Dizziness Handicap Inventory were not completed for this group. 
Data Analysis 
Gait data consisted of GM data collected under three conditions: self-selected 
speed (SSS), fast speed (FS), and during head turning (HT), from both groups of subjects.  
The gait measures included gait speed, support base, double support time, and time from 
heel contact to forefoot contact (HA-I).  Gait speed, support base, and double support 
time were examined because numerous authors have found them to be abnormal in 
subjects with vestibulopathy or balance deficits.13, 40, 47  Time from heel contact to 
forefoot contact was examined because of the repeated findings of abnormality in this 
variable by Ishikawa et al.10, 11, 12 
It is likely that two of the GM measures, double support time and time from heel 
contact to forefoot contact (HA-I), could be affected by gait speed.  Double support time 
is inversely proportional to gait speed.60  That is, as an individual walks faster, double 
support time decreases.  HA-I is the time from heel contact to forefoot contact and is 
therefore related to the gait task of weight acceptance.61  The assumption was made that 
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HA-I would vary inversely with gait speed.  As an individual walks faster, weight 
acceptance would occur more quickly, resulting in more rapid transition of weight from 
the heel to the forefoot.  The effect of gait speed could impair the ability to compare 
double support time and HA-I within or between subjects.  Therefore, these values were 
“normalized” by converting each to a percentage of cycle time, using the subject’s mean 
cycle time for the condition being examined.  For each subject, cycle time was calculated 
for each stride under each condition (self-selected speed, fast speed, and head turning), by 
adding stance time and swing time for each stride.  The mean was determined for each 
condition and used when expressing double support time and HA-I as a percentage of 
cycle time. 
Additional measures collected from the subjects with UVH, before and after VR, 
included Dizziness Handicap Inventory (DHI) score and EquiTest Composite 
Equilibrium Score (SOT-C). 
Raw data from subjects in both groups is found in Appendix G (page 93).  All 
statistical analyses were performed with SPSS for Windows, Release 11.0.01.62 
GM Data 
Preliminary Analyses by Subject Group 
The support base and double support time data collected using the GM is reported 
according to right and left sides, and by trial.  Each subject performed four trials under 
each condition.  To determine whether there was a significant difference between sides or 
between trials, for double support time and base of support, a three-way repeated 
measures analysis of variance was performed for subjects with UVH before VR, subjects 
with UVH after VR, and for subjects without vestibular pathology.  The three factors 
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were SIDE, CONDITION, and TRIAL.  The SIDE factor had two levels: affected and 
unaffected for subjects with UVH, or right and left for subjects without vestibular 
pathology.  The CONDITION factor had three levels: self-selected speed (SSS), fast 
speed (FS), and head turning (HT).  The TRIAL factor had four levels: trial 1, trial 2, trial 
3, and trial 4.  The alpha level was set at 0.05. 
Speed data collected by the GM is reported according to trial.  To determine 
whether there was a significant difference between trials, a two-way repeated measures 
analysis of variance was performed for subjects with UVH before VR, subjects with 
UVH after VR, and subjects without vestibular pathology.  The two factors were 
CONDITION and TRIAL.  The CONDITION factor had three levels: SSS, FS, and HT.  
The TRIAL factor had four levels:  trial 1, trial 2, trial 3, and trial 4.  Alpha level was set 
at 0.05. 
When HA-I was determined using the previously described technique, trial was 
not reported.  To determine whether there was a significant difference between sides or 
conditions, a two-way repeated measures analysis of variance was performed for subjects 
with UVH before VR, subjects with UVH after VR, and for subjects without vestibular 
pathology.  The two factors were SIDE and CONDITION.  The SIDE factor had two 
levels: affected and unaffected for subjects with UVH, or right and left for subjects 
without vestibular pathology.  The CONDITION factor had three levels: SSS, FS, or HT.  
The alpha level was set at 0.05. 
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Analyses Across Groups 
To examine the change in gait variables in the subjects with UVH before and after 
VR, paired t-tests were performed for gait speed, base of support, double support time, 
and HA-I for each condition. 
To determine whether there was a significant difference among subjects without 
vestibular pathology, subjects with UVH before VR and after VR, or among walking 
conditions, for each gait variable, a two-way repeated measures analysis of variance was 
performed.  The two factors were CATEGORY and CONDITION.  The CATEGORY 
factor had three levels: UVH before VR, UVH after VR, and no vestibular pathology.  
The CONDITION factor had three levels: self-selected speed, fast speed, and head 
turning.  The alpha level was set at 0.05. 
Because an interaction was found between CATEGORY and CONDITION for 
gait speed, a series of six one-way repeated measures analyses of variance was conducted 
to identify the source of interaction.  The table below describes the analyses: 
 
 
Table 13. — One-Way Repeated Measures Analysis of Variance for Speed 
 
Group Comparison 
UVH pre-VR SSS FS HT 
UVH post-VR SSS FS HT 
No vestibular pathology SSS FS HT 
SSS UVH Pre-VR UVH Post-VR No pathology 
FS UVH Pre-VR UVH Post-VR No pathology 
HT UVH Pre-VR UVH Post-VR No pathology 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
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The validity of the use of GM gait variables as a measure in subjects with UVH is 
supported if the GM gait variables can be used to predict whether or not a subject has 
UVH.  To investigate whether the gait variables collected using the GM can predict 
group membership, a stepwise discriminant analysis was performed.52  A discriminant 
analysis develops a statistical model that describes the existing groups and that can be 
used to predict group membership.  The discriminant analysis was used to investigate 
speed, support base, double support time, and HA-I under the three test conditions (self-
selected speed, fast speed, and head turning) in subjects with UVH before VR and the 
matched subjects without vestibular pathology. 
Comparison of GM Data and Other Measures 
Paired t-tests were performed to investigate the changes in gait variables, DHI 
scores, and SOT-C scores with VR. 
To investigate the relationship between the gait variables collected with the GM 
and the Dizziness Handicap Inventory and computerized posturography testing for 
subjects with UVH after VR, a series of Pearson product moment correlations was 
calculated. 
Another approach to examining the relationship between the gait variables 
collected with the GM and the Dizziness Handicap Inventory and computerized 
posturography testing is the use of effect size.  Effect size is a standardized measure of 
change, and can be used to compare the changes between different measures.63  The 
method used to calculate effect size was described by Kazis and involves taking the 
difference between the means before treatment and after treatment and dividing it by the 
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standard deviation of the same measure before treatment.  Effect size indicates the 
responsiveness of an instrument, or its ability to detect change over time.52 
Results 
GM Data 
Preliminary Analyses by Groups 
For each analysis of variance, an analysis of variance summary table and pairwise 
comparison table are found in Appendix H (page 96). 
Support Base 
Three-way repeated measures analyses of variance were conducted on support 
base in subjects with UVH before VR, subjects with UVH after VR, and subjects without 
vestibular pathology.  Results are summarized in Table 14.  No effect was found for 
SIDE, indicating no significant difference in the support base values between right and 
left sides for all subjects.  No effect was found for TRIAL, indicating that for all subjects, 
support base did not vary across walking trials in a given condition.  Because of these 
findings, in subsequent analyses, support base data for all subjects was consolidated 
across sides and trials.  No interaction effects were found among any of the factors.  A 
significant effect was found for CONDITION, indicating significant differences in 
support base between gait at self-selected speed and gait with head turning. 
Double Support Time 
Three-way repeated measures analyses of variance were conducted on double 
support time as a percent of gait cycle in subjects with UVH before VR, subjects with 
UVH after VR, and subjects without vestibular pathology.   
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Table 14. — Summary of Preliminary Analyses: Support Base 
 
 Side Trial Condition 
UVH Pre-VR No effect No effect SSS vs. HT* 
UVH Post-VR No effect No effect SSS vs. HT* 
No pathology No effect No effect SSS vs. HT* FS vs. HT* 
*Significant at α = 0.05  
 
 
 
Results are summarized in Table 15.  No effect was found for SIDE, indicating no 
significant difference in the double support time between right and left sides for all 
subjects.  No effect was found for TRIAL, indicating that for all subjects, double support 
time did not vary across walking trials in a given condition.  Because of these findings, in 
subsequent analyses, double support time data for all subjects was consolidated across 
sides and trials.  No interaction effects were found among any of the factors.  A 
significant effect was found for CONDITION, indicating significant differences in 
double support time between gait at self-selected speed and gait with head turning, and 
between fast speed gait and gait with head turning. 
 
 
Table 15. — Summary of Preliminary Analyses: Double Support Time 
 
 Side Trial Condition 
UVH Pre-VR No effect No effect SSS vs. FS* FS. vs. HT* 
UVH Post-VR No effect No effect SSS vs. FS* FS vs. HT* 
No pathology No effect No effect SSS vs. FS* FS vs. HT* 
*Significant at α = 0.05  
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Gait Speed 
Three-way repeated measures analyses of variance were conducted on gait speed 
in subjects with UVH before VR, subjects with UVH after VR, and subjects without 
vestibular pathology.  Results are summarized in Table 16.  No effect was found for 
TRIAL, indicating that for all subjects, gait speed did not vary across walking trials in a 
given condition.  Because of these findings, in subsequent analyses, gait speed data for all 
subjects was consolidated across trials.  No interaction effects were found among any of 
the factors.  A significant effect was found for CONDITION, indicating significant 
differences in gait speed between gait at self-selected speed and fast speed gait, and 
between fast speed gait and gait with head turning. 
 
 
Table 16. — Summary of Preliminary Analyses: Speed 
 
 Trial Condition 
UVH Pre-VR No effect SSS vs. FS* FS vs. HT* 
UVH Post-VR No effect SSS vs. FS* FS vs. HT* 
No pathology No effect SSS vs. FS* FS. vs. HT* 
*Significant at α = 0.05  
 
HA-I 
Three-way repeated measures analyses of variance were conducted on HA-I as a 
percent of gait cycle in subjects with UVH before VR, subjects with UVH after VR, and 
subjects without vestibular pathology.  Results are summarized in Table 17.  No effect 
was found for SIDE, indicating that for all subjects, HA-I did not vary across sides in a 
given condition.  Because of these findings, in subsequent analyses, HA-I data for all 
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subjects was consolidated across sides.  No interaction effects were found among any of 
the factors.  No effect was found for CONDITION, indicating no significant differences 
in HA-I between gait at self-selected speed and fast speed gait, and between fast speed 
gait and gait with head turning. 
 
 
Table 17. — Summary of Preliminary Analyses: HA-I 
 
 Side Condition 
UVH Pre-VR No effect No effect 
UVH Post-VR No effect No effect 
No pathology No effect No effect 
 
 
 
Analyses Across Groups 
The paired t-tests conducted on speed, support base, double support time, and 
HA-I for subjects with UVH, before and after VR are summarized in Table 18.  No 
significant difference was found in any gait variable between conditions, i.e., before and 
after VR. 
For each analysis of variance, an analysis of variance summary table and pairwise 
comparison table are found in Appendix I (page 106).  Table 19 contains a summary of 
the results of the two-way ANOVAs conducted on the gait variables between groups. 
A two-way analysis of variance was conducted on speed.  An interaction effect 
was found for the CATEGORY-CONDITION interaction.  To identify the source of the 
interaction, a series of one-way ANOVAs was performed.  The findings of these one-way 
repeated measures analyses of variance and pairwise comparisons identified the source of 
significant interaction is:  speed at self-selected speed is not significantly different among 
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subjects with UVH before VR, subjects with UVH after VR, and subjects without 
vestibular pathology.  Self-selected speed, considered as an individual variable, is 
therefore not useful in detecting whether a subject has UVH. 
 
 
Table 18. — Pre-Post VR Comparison of Gait Variables in Subjects with UVH 
 
Variable Pair Mean SD t Sig N 
Pre RehabSSS Speed (m/s) 
Post Rehab SSS Speed (m/s) 
.787 
.870 
.194 
.135 -1.52 .161 
11 
11 
Pre Rehab FS Speed (m/s) 
Post Rehab FS Speed (m/s) 
1.238 
1.197 
.262 
.247 .569 .582 
11 
11 
Pre Rehab HT Speed (m/s) 
Post Rehab HT Speed (m/s) 
.707 
.784 
.267 
.154 -1.163 .272 
11 
11 
Pre Rehab SSS BOS (m) 
Post Rehab SSS BOS (m) 
.149 
.154 
.101 
.100 -.304 .768 
11 
11 
Pre Rehab FS BOS (m) 
Post Rehab FS BOS (m) 
.156 
.164 
.107 
.098 -.445 .666 
11 
11 
Pre Rehab HT BOS (m) 
Post Rehab HT BOS (m) 
.187 
.172 
.104 
.105 .766 .461 
11 
11 
Pre Rehab SSS DST (% of gait cycle) 
Post Rehab SSS DST (% of gait cycle) 
23.947 
21.979 
6.051 
5.562 1.376 .199 
11 
11 
Pre Rehab FS DST (% of gait cycle) 
Post Rehab FS DST (% of gait cycle) 
20.926 
17.942 
6.383 
2.701 1.259 .237 
11 
11 
Pre Rehab HT DST (% of gait cycle) 
Post Rehab HT DST (% of gait cycle) 
27.005 
28.106 
6.991 
9.723 -.305 .766 
11 
11 
Pre Rehab SSS HA-I (% of gait cycle) 
Post Rehab SSS HA-I (% of gait cycle) 
25.216 
26.338 
7.835 
7.603 -.703 .498 
11 
11 
Pre Rehab FS HA-I (% of gait cycle) 
Post Rehab FS HA-I (% of gait cycle) 
24.902 
24.718 
8.641 
10.079 .100 .922 
11 
11 
Pre Rehab HT HA-I (% of gait cycle) 
Post Rehab HT HA-I (% of gait cycle) 
29.237 
27.073 
9.611 
8.603 1.206 .256 
11 
11 
 
 
 
A two-way analysis of variance was conducted on support base.  No effect was 
found for interaction or CATEGORY, but an effect was found for CONDITION.  The 
significant differences were found between gait at self-selected speed and with head 
turning, and between gait at fast speed and with head turning. 
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A two-way analysis of variance was conducted on double support time as a 
percentage of cycle time.  No effect was found for interaction, but an effect was found for 
CATEGORY.  The significant differences were found between subjects with UVH before 
VR and subjects without vestibular pathology, and between subjects with UVH after VR 
and subjects without vestibular pathology.  An effect was found for CONDITION.  The 
significant differences were found between gait at self-selected speed and with head 
turning, and between gait at fast speed and with head turning. 
A two-way analysis of variance was conducted on HA-I as a percentage of cycle 
time.  No effect was found for CATEGORY, CONDITION, or interaction. 
 
 
Table 19. — Summary of Two-Way ANOVAs for Category and Condition 
 
Gait Variable Category Condition 
Support Base No Effect SSS vs. HT* FS vs. HT* 
Double Support 
Time 
UVH Pre-VR vs. No pathology* 
UVH Post-VR vs. No pathology* 
SSS vs. HT* 
FS vs. HT* 
HA-I No Effect No Effect 
*Significant at α = 0.05  
 
 
Group Prediction 
The stepwise discriminant analysis indicated that in this sample, the variables that 
predict group membership are double support time in the fast speed condition and double 
support time during head-turning gait.  These variables were able to classify subjects 
without vestibular pathology with 100% accuracy and subjects with UVH with 90.9% 
accuracy.  Results are summarized in Tables 20 and 21. 
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Table 20. — Discriminant Function Variables 
 
Step Variables F ratio p value 
1 HT DST 47.500 .000 
2 FS DST 32.961 .000 
FS = Fast speed 
HT = Head turning 
DST = Double support time 
N = 22 subjects total (11 UVH pre-VR, 11 without pathology) 
 
 
 
Table 21. — Classification Accuracy: HT DST & FS DST 
 
Predicted Group Membership 
Actual: UVH PreRehab No Pathology 
UVH PreRehab 90.9% n = 10 
9.1% 
n = 1 
No Pathology 0% n = 0 
100% 
n = 11 
 
 
 
Changes in DHI and Computerized Posturography 
Paired t-tests revealed significant improvement in total Dizziness Handicap 
Inventory (DHI) scores, in physical and functional DHI subscores, and in composite SOT 
scores (SOT-C).  Results are summarized in Table 22. 
Comparison Between Gait Variables, DHI, and Computerized 
Posturography 
Pearson product-moment correlations between the gait variables and DHI scores 
indicated only one significant correlation, between double support time in the self-
selected speed condition and DHI score, with r = -.640, which is considered a moderate to 
good relationship.52  Pearson product-moment correlations between the gait variables and 
computerized posturography score (SOT-C) indicated no significant correlations.  
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Table 22. — Effect of VR on DHI and Computerized Posturography Scores 
 
Variable Pair Mean SD t Sig. N 
Pre Rehab DHI-Total 
Post Rehab DHI-Total 
43.27 
25.09 
21.91 
20.46 
4.64 .001* 11 
11 
Pre Rehab DHI-Physical 
Post Rehab DHI-Physical 
16.00 
8.73 
7.75 
6.94 
4.54 
 
.001* 11 
11 
Pre Rehab DHI-Emotional 
Post Rehab DHI-Emotional 
11.09 
7.82 
7.56 
9.10 
1.80 .101 11 
11 
Pre Rehab DHI-Functional 
Post Rehab DHI-Functional 
16.18 
8.55 
11.22 
6.58 
2.69 .023* 11 
11 
Pre Rehab SOT-C 
Post Rehab SOT-C 
56.91 
74.64 
11.06 
7.32 
-4.88 .001* 11 
11 
*Significant at α = 0.05 
 
DHI-Total = Total Dizziness Handicap Inventory score 
DHI-Physical = Physical subscore of Dizziness Handicap Inventory 
DHI-Emotional = Emotional subscore of Dizziness Handicap Inventory 
DHI-Functional = Functional subscore of Dizziness Handicap Inventory 
SOT-C = Composite Sensory Organization Test score 
 
 
 
Effect sizes were calculated for the GM gait variables, DHI total and subscores, 
and computerized posturography scores (SOT-C), using the formula (m1– m2)/s1, where 
m1 is the pretreatment mean, m2 is the posttreatment mean, and s1 is the pretreatment 
standard deviation.  Effect sizes are summarized in Appendix J (page 110).  An effect 
size of 0.2 is small, 0.5 is moderate, and 0.8 or greater is large.64  The effect sizes for DHI 
and SOT-C were large, and the effect sizes for the GM gait variables were very small.  
These findings indicate that the gait variables did not demonstrate the same degree of 
responsiveness to change as the DHI and computerized posturography. 
Discussion 
The first question addressed by this study was whether there were changes in gait 
variables measured with the GM in adults with unilateral vestibular hypofunction after 
VR.  No significant difference was found following VR in any of the measured gait 
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variables.  Appendix G (page 93) contains means and standard deviations for the subjects 
with UVH before and after VR.  However, after VR, the GM variables for subjects with 
UVH continued to be significantly different than those for subjects without vestibular 
pathology.  These findings are consistent with those of Allum et al, who found that 
subjects with UVH continued to display deficits during complex gait tasks after three 
months.36   
The means and standard deviations for the GM variables are found in Appendix K 
(page 111).  Examination of the standard deviations for DST reveals lower standard 
deviations after VR, an indication of reduced variability.  The standard deviations for 
HA-I are higher after VR, an indication of increased variability. 
The second question addressed by this study was whether gait variables measured 
with the GM can predict if an individual has UVH.  Results of the discriminant analysis 
are found in Table 21 (page 59).  For this sample, for all subjects, gait data collected with 
the GM could predict whether a subject had UVH with 90.9% accuracy and whether a 
subject did not have unilateral vestibular pathology with 100% accuracy.  The results of 
this study support the predictive validity of the GaitMat II. 
Sensitivity and Specificity 
The term “sensitivity” refers to the ability of a diagnostic test to detect a condition 
when the condition is actually present.65  The model developed by the discriminant 
analysis using FS DST and HT DST was able to classify subjects with UVH with 90.9% 
accuracy, indicating a high degree of sensitivity. 
The term “specificity” refers to the ability of a diagnostic test to detect the 
absence of a condition when the condition is actually absent.65  The model developed by 
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the discriminant analysis using FS DST and HT DST was able to classify subjects 
without vestibular pathology with 100% accuracy, indicating a high degree of specificity.  
The third question addressed by this study was whether there is a relationship 
between the changes in gait variables as measured with the GaitMat II and other clinical 
measures in adults with unilateral vestibular hypofunction after VR.  The effect sizes for 
the GM gait variables, DHI, and SOT-C are summarized in Appendix J (page 110).  The 
results of this study indicate that gait variables as measured with the GM are not affected 
by VR in the same manner as other clinical measures. 
Gait Variables 
Support Base 
Means and standard deviations for base of support can be reviewed in Table 57, 
page 111, and results of the analysis of variance can be reviewed in Table 49, page 107.  
No significant difference was found in base of support in subjects with UVH before or 
after VR or in subjects without pathology.  This is consistent with the finding of Krebs et 
al,50 who found that BOS was not abnormal in patients with vestibular pathology.  Base 
of support for all subjects was larger when walking with head turning, regardless of 
speed.  This might be expected, since walking with head turning places greater demands 
on the postural control system, requiring compensatory increase in support base. 
Double Support Time 
Means and standard deviations for double support time can be reviewed in Table 
58, page 111, and results of the analysis of variance can be reviewed in Table 52, page 
108.  A significant difference was found in double support time between subjects with 
UVH, before or after VR, and in subjects without vestibular pathology.  This is consistent 
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with Tucker et al,13 Ishikawa et al,10, 11, 12 and Conrad et al,18 who found that subjects 
with vestibular pathology had increased double support time compared with subjects 
without vestibular pathology. 
HA-I 
Means and standard deviations for HA-I can be reviewed in Table 59, page 112, 
and results of the analysis of variance can be reviewed in Table 55, page 109.  No 
significant difference was found in HA-I (time from heel contact to forefoot contact) for 
any group under any of the three conditions.  This is in contrast to the findings of 
Ishikawa et al.10, 11, 12  The studies by Ishikawa et al reported a high incidence of 
abnormality in HA-I in subjects with vestibulopathy, whereas the current study compared 
differences in HA-I values among subjects with UVH before VR, subjects with UVH 
after VR, and subjects without vestibular pathology.  The studies by Ishikawa et al do not 
provide HA-I means or standard deviations and appear to have made no correction for 
gait speed.  The current study calculated HA-I as a percentage of the gait cycle, which 
controlled for gait speed.  Together, these differences in methodology limit the ability to 
make comparisons between the HA-I values in the Ishikawa studies and the current study. 
Gait Speed 
Means and standard deviations for speed can be reviewed in Tables 66, 67, and 
68, pages 114 and 115, and results of the analysis of variance can be reviewed in Table 
47, page 106.  For all subjects, self-selected speed was slower than fast speed.  This is 
consistent with the findings of Krebs et al, who found that subjects with vestibular 
dysfunction were capable of walking faster than their self-selected gait speed.9 
 64
Fast gait speed for all subjects with UVH was lower than that for subjects without 
vestibular pathology, as was gait speed while performing active head turns.  However, 
there was no significant difference in self-selected speed among subjects with UVH 
before VR, subjects with UVH after VR, and subjects without pathology.  This is not 
consistent with the findings of Krebs et al, who found a significant increase in self-
selected speed in subjects with vestibular pathology after participating in VR.9  This may 
be related to the subject populations who participated in the studies.  The subjects in the 
Krebs et al study had a diagnosis of bilateral vestibular hypofunction (BVH), and those in 
this study had a diagnosis of unilateral vestibular hypofunction.  BVH is a diagnosis that 
is likely to result in greater gait impairment than UVH.  These subjects had the potential 
for a greater amount of improvement in gait speed than those with UVH. 
Other Clinical Measures 
The results of this study (Table 22, page 60) indicated improvement in the total 
DHI score and in the physical and functional DHI subscores with VR.  This is consistent 
with the findings of other researchers.66, 9, 33, 34, 37, 35  The results of this study also 
indicated improvement in SOT-C scores with VR.  This is consistent with the findings of 
other researchers. 31, 6, 29 
Statistical Power 
The term statistical power refers to the chance of correctly detecting a difference 
between groups when a difference exists.  Inferring from statistical analysis that no 
difference exists between groups when the groups are actually different is referred to as a 
Type II error.67  The higher the power, the less likely one is to commit a Type II error.  
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The factors that affect the power of a study are the sample size, the level of statistical 
significance, the variability of the samples, and the effect size.67   
Preliminary Analyses by Group 
The statistical power for the preliminary analyses of variance by groups is 
summarized in Table 23. 
Sample Size 
Small sample sizes are less likely to accurately represent population 
characteristics, and power is reduced.52  The sample size used in this study was 11 
subjects with UVH matched with 11 subjects without vestibular pathology.  The small 
sample size influenced the low power of the analyses conducted on the GM data. 
 
 
Table 23. — Statistical Power for Preliminary Analyses by Group 
 
Variable Group Side: 
Power 
Trial: 
Power 
Support Base UVH Pre-VR 0.055 0.296 
 UVH Post-VR 0.050 0.239 
 No Pathology 0.150 0.189 
    
Double Support Time UVH Pre-VR 0.052 0.315 
 UVH Post-VR 0.203 0.373 
 No Pathology 0.166 0.653 
    
HA-I UVH Pre-VR 0.060 N/A 
 UVH Post-VR 0.053 N/A 
 No Pathology 0.054 N/A 
    
Speed UVH Pre-VR N/A 0.241 
 UVH Post-VR N/A 0.347 
 No Pathology N/A 0.311 
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Statistical Significance 
Inferring from statistical analysis that a difference exists between groups when 
there is no difference is referred to as a Type I error.  As the alpha level is reduced, the 
chance of Type I error decreases, but the chance of Type II error increases.67  The alpha 
level used in this study was 0.05. 
Variance 
The effect of variance on power is: as variance within the data set decreases, 
power increases.  When the variance within groups is small, detecting differences 
between the groups is more likely.  When the variance within groups is large, differences 
between them are less obvious.52  The raw GM data, presented by side and by trial, are 
located in Appendix K (page 111).  The raw GM data includes means and standard 
deviations for each variable.  Standard deviation is the square root of the variance, and is 
expressed in the same unit as the variable.  A review of the GM data by side and by trial 
reveals that the standard deviations for each GM variable are quite large.  The large 
amount of variance reduces statistical power. 
Effect Size 
When referring to power, the term effect size refers to the degree of difference 
between the groups.  Determining the minimal clinically significant effect size is based 
on judgment, not statistical analysis.67 
Side 
There is no consensus on the degree of difference between sides for gait variables 
that would be considered significant.  The gait literature does not typically include gait 
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variables broken down according to side.60  For movement variables such as grip strength 
and isokinetic muscle force production, a difference between sides of up to 20% has been 
shown to be present in subjects without pathology.68, 69, 70, 71  A review of the GM data 
for this study (Appendix K, page 111) reveals that the difference between sides for gait 
variables in subjects without vestibular pathology ranged from 0% to 20%.  The 
difference between sides for gait variables in subjects with UVH ranged from 0% to 10% 
before VR, and from 0% to 27% after VR.  For the present sample of subjects with UVH, 
there is no evidence of a consistent pattern of differences between affected and 
unaffected side, and the degree of difference between sides is similar to that found in the 
subjects without vestibular pathology.  Statistical analyses indicated no significant 
differences between sides. Although the statistical power for these analyses were low, the 
conclusion that there is no difference between sides appears reasonable. 
Trial 
A review of the GM data for trials reveals that the difference among trials for gait 
parameters in subjects without vestibular pathology ranged from less than 1% to 28%.  
The difference among trials for gait variables in subjects with UVH ranged from 0% to 
15% before VR, and from 0% to 47% after VR.  There is no evidence of a consistent 
pattern of differences among gait trials, and the degree of difference among trials is 
similar to that found in the subjects without vestibular pathology. 
Analyses Across Groups 
The statistical power for the analyses of variance across groups is summarized in 
Table 24. 
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Table 24. — Statistical Power for Analyses Across Groups 
 
Variable Category Factor Power Condition Factor Power 
Support 
Base No effect 0.760 
SSS vs. HT 
FS vs. HT 0.996 
     
Double 
Support 
Time 
UVH Pre-VR vs. Normal 
UVH Post-VR vs. Normal 1.00 
SSS vs. HT 
FS vs. HT 0.987 
     
HA-I No effect 0.077 No effect 0.819 
 
 
 
The only analysis across groups that does not have acceptable statistical power is 
the analysis for the effect of CATEGORY (subject group) on HA-I (time from heel 
contact to forefoot contact), which was 0.077.  The data used for these analyses are 
located in Appendix G (page 93).  The small sample size (n = 11), high levels of variance 
in all 3 groups (UVH before VR, UVH after VR, and no vestibular pathology), and small 
effect size all played a role in the low power. 
Strengths of the Present Study 
This study collected gait data from subjects with vestibular pathology as they 
walked while turning their heads. This type of gait analysis was urged by Mulder et al in 
their review of clinical gait analyses.72  They found that only 15 of the 96 articles 
reviewed used simultaneous tasks to examine gait function, and noted a “discrepancy 
between what is needed for disability-oriented gait assessment and what is used in gait 
assessment labs.”  Mulder et al indicated a need to incorporate stressors such as 
performance of dual tasks into gait analysis in order to determine disability rather than 
focusing on gait impairments. 
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This study incorporated several assessments to examine the effects of VR in 
subjects with UVH:  the DHI, a self-reported assessment of disability; CDP, an 
assessment of static postural control; and GM, and assessment of dynamic gait function.  
This is in keeping with Clendaniel,73 who stated that to examine functional outcomes, 
“the most appropriate measurement tool is a combination of a self-perceived functional 
limitations test and appropriate measures of physical performance for the particular 
patient population.” 
For HA-I and double support time, values were reported as a percentage of cycle 
time.  These variables can demonstrate velocity-dependence, and therefore this correction 
should account for the effect of velocity.60 
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CHAPTER 8: CONCLUSIONS AND SUMMARY 
GM Reliability and Validity 
The first, second, and third studies investigated three GM systems and determined 
that there were significant differences in interswitch distances at the junctions of GM 
panels.  An error analysis demonstrated that these differences in interswitch distances are 
not clinically significant for gait analysis. 
The fourth study compared a known signal simultaneously collected with the GM 
system and a “gold standard,” the Vicon 370 motion analysis system.  Temporal 
measurements taken by the two systems had an ICC value of 0.99, indicating excellent 
reliability.  Distance measurements taken by the two systems had an ICC value of 0.24, 
indicating poor to moderate reliability.  The mean difference between distance measures 
taken with the Vicon and the GM was only 11.7 mm, a difference that would be clinically 
significant only for support base measurements.  These results support the reliability and 
concurrent validity of the GM. 
The fifth study examined gait variables collected with the GM in subjects with 
UVH before VR, subjects with UVH after VR, and subjects without known pathology 
who were matched for age, gender, weight, and height.  A discriminant analysis was used 
to determine that double support time at fast walking speed and with head turning 
predicted whether a subject had UVH with 90.9% accuracy and whether a subject did not 
have UVH with 100% accuracy, indicating very good sensitivity and specificity.  These 
results support the predictive validity of the GM used as an instrument in VR. 
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Sample Size 
In this study, no significant difference was found in subjects with UVH following 
VR for any GM variable.  This may result from the small sample size.  Using the GM 
data from the present study, sample sizes needed to obtain a power of 0.80 with α = 0.5 
were calculated as described by Portney.52  The results of sample size analysis are 
summarized in Table 25.  A review of the analyses indicates that for some GM variables, 
sample sizes of 30 to 64 subjects would be needed.  These GM variables are speed at self-
selected speed and with head turning, double support time at self-selected speed and at 
fast speed, and HA-I during head turning.  As per Table 25, for all other GM variables 
recruiting sufficient subjects to achieve the samples sizes needed to obtain sufficient 
power would be prohibitive. 
 
 
 
Table 25.  Summary of Sample Size Analyses 
 
GM Variable Change Score Mean 
Change Score 
Standard 
Deviation 
Sample Size 
Needed for Power 
of 0.80 
Speed: SSS -0.083 0.18 30 
Speed: FS 0.041 0.24 215 
Speed: HT -0.077 0.22 64 
BOS: SSS -0.005 0.06 732 
BOS: FS -0.008 0.06 343 
BOS: HT 0.015 0.07 114 
DST: SSS 1.968 4.74 37 
DST: FS 2.984 7.86 43 
DST: HT -1.101 11.96 732 
HA-I: SSS -1.122 5.29 175 
HA-I: FS 0.184 6.10 7720 
HA-I: HT 2.164 5.95 49 
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Suggestions for Future Research 
Future studies should examine larger numbers of subjects with UVH to determine 
if the results of the present study are representative of the gait changes that occur 
following VR in subjects with UVH.  The results of the clinical study indicate that 
subjects with UVH continue to display gait abnormalities after VR.  However, the small 
sample size in the current study limits the generalizability of the findings to the larger 
population of individuals with UVH.  These findings suggest that further investigation of 
the nature of VR for individuals with UVH might be warranted.  It might be worthwhile 
to consider incorporating specific gait training activities into the VR programs for 
individuals with UVH. 
It should be remarked that recruiting a sufficient number of subjects with UVH is 
an ambitious endeavor, and will likely involve recruitment of subjects at numerous 
facilities.  Because the GM has been shown to demonstrate good accuracy, validity, and 
reliability, it is a measure that could be useful in studying the gait of individuals with 
UVH.  Its relative portability will facilitate collection of gait data from subjects with 
UVH in a variety of locations. 
Another area of emphasis for future study of subjects with UVH is examination of 
the effect of VR on the variability of GM measures.  Analysis of the GM data collected 
from subjects with UVH indicates that for DST and HA-I, the variability changed 
following VR.  Previous research has suggested that it is possible that one of the effects 
of intervention is alteration in the variability of measures.74  Future studies should 
examine the effects of intervention on variability of GM measures, in addition to the 
means of the measures. 
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Appendix A. Interswitch Distances 
 
 
Panel Intersections 
Longitudinal    Transverse   
TUSPM Arcadia USP  TUSPM Arcadia USP 
       
16.99 17.37 17.83  22.19 17.48 19.46 
16.93 17.02 17.83  21.23 17.21 19.86 
16.41 17.75 17.66  19.04 17.43 19.20 
16.80 17.98 17.70  21.23 17.78 18.30 
17.15 17.41 18.28  19.89 17.28 18.58 
17.22 20.17 18.41  19.17 18.16 19.05 
16.55 19.56 19.93  19.25 18.01 20.06 
17.28 18.79 18.59  19.60 17.34 19.88 
17.69 19.13 17.85  19.47 16.36 18.63 
17.02 18.80 18.44  20.25 16.48 19.32 
15.94 16.94 18.56  22.55 17.03 18.08 
17.11 17.46 18.11  22.69 17.11 18.65 
17.52 18.25 18.68  20.91 17.83 18.69 
17.35 19.01 18.34  20.04 18.45 19.17 
18.44 18.32 19.23  19.99 17.85 18.76 
 
Sheet Intersections 
TUSPM Arcadia USP 
17.35 15.76 15.53 
16.66 16.01 15.54 
16.56 15.98 15.54 
14.99 16.62 16.34 
15.33 17.33 16.78 
15.10 16.65 16.48 
15.23 16.85 15.46 
15.82 17.04 16.38 
16.29 17.27 15.14 
15.41 17.02 16.48 
15.88 17.21 16.13 
16.37 16.55 15.04 
16.12 17.14 14.77 
16.57 16.93 15.65 
15.85 17.43 16.31 
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Regular 
Longitudinal Transverse 
TUSPM Arcadia USP TUSPM Arcadia USP 
  
14.45 15.22 14.66 14.13 14.87 14.66 
13.45 15.73 15.02 15.11 14.71 14.77 
12.85 14.78 14.62 14.70 14.77 15.17 
14.41 15.47 14.44 15.15 14.82 14.44 
14.16 15.34 14.59 14.83 14.83 14.78 
14.18 14.78 15.37 14.63 14.39 14.98 
14.33 14.56 14.89 14.73 15.16 15.22 
14.15 15.31 15.51 15.54 14.51 14.97 
14.42 14.83 15.19 14.68 14.44 15.29 
14.24 15.31 15.04 14.40 14.62 14.48 
14.43 15.18 14.87 14.98 14.48 15.30 
13.99 14.42 14.88 15.06 15.24 15.84 
14.51 14.97 15.14 14.76 14.76 14.90 
14.49 15.02 15.68 15.15 14.68 14.51 
14.74 14.91 14.79 14.39 14.94 14.61 
  82 
 
Appendix B. Dizziness Handicap Inventory 
 
 
Name:  Date:  
    
Instructions: The purpose of this scale is to identify difficulties that you may be experiencing because of 
your dizziness or unsteadiness.  Please answer “yes,” “no,” or “sometimes” to each question.  Answer each 
question as it pertains to your dizziness or unsteadiness problem only. 
   Yes  No  Some 
times 
P1. Does looking up increase your problems?       
E2. Because of your problem, do you feel 
frustrated? 
      
F3. Because of your problem, do you restrict your 
travel for business or recreation? 
      
P4. Does walking down the aisle of a supermarket 
increase your problem? 
      
F5. Because of your problem, do you have 
difficulty getting into or out of bed? 
      
F6. Does your problem significantly restrict your 
participation in social activities such as going 
out to dinner, the movies, dancing, or to 
parties? 
      
F7. Because of your problem, do you have 
difficulty reading? 
      
P8. Does performing more ambitious activities 
like sports or dancing or household chores 
such as sweeping or putting dishes away 
increase your problem? 
      
E9. Because of your problem, are you afraid to 
leave your room without having someone 
accompany you? 
      
E10. Because of your problem, are you 
embarrassed in front of others? 
      
P11. Do quick movements of your head increase 
your problem? 
      
F12. Because of your problem, do you avoid 
heights? 
      
P13. Does turning over in bed increase your 
problem? 
      
F14. Because of your problem, is it difficult for 
you to do strenuous housework or yardwork? 
      
E15. Because of your problem, are you afraid 
people may think you are intoxicated? 
      
F16. Because of your problem, is it difficult for 
you to walk by yourself? 
      
P17. Does walking down a sidewalk increase your 
problem? 
      
E18. Because of your problem, is it difficult for 
you to concentrate? 
      
F19. Because of your problem, is it difficult for 
you to walk around your house in the dark? 
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E20. Because of your problem, are you afraid to 
stay home alone? 
      
E21. Because of your problem, do you feel 
handicapped? 
      
E22. Has your problem placed stress on your 
relationships with members of your family or 
friends? 
      
E23. Because of your problem, are you depressed?       
F24. Does your problem interfere with your job or 
household responsibilities? 
      
P25. Does bending over increase your problem?       
 
Total 
      
   (x4)  (x4)  (x4) 
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Appendix C. Sample EquiTest Posturography Results 
 
 
 
 
Figure 7. — EquiTest sensory organization test 
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Appendix D. Medical Information: UVH Group 
 
 
 
# Side of Lesion Diagnosis 
Onset – 
Office Visit PMH Medications 
11 Left Left peripheral lesion 
2/14/01 – 
4/16/01 N/A N/A 
12 Left Left peripheral lesion 
1/02 - 
3/1/02 
C/S laminectomy, 
Hypercholestemia Lipitor 
13 Left Left vestibular neuritis 
4/24/02 – 
5/22/02 HTN Toprol 
14 Right Right vestibular neuritis 
12/1/00 - 
1/2/01 L/S surgery 1990 
Oxycotin, 
Percocet, Valium 
15 Right Right vestibular neuritis 
4/1/01 – 
5/31/01 
Hernia, Kidney 
Stones N/A 
16 Left Left vestibular loss 
6/2/01 – 
7/10/01 HTN, DM 
Amaryl, HCTZ, 
Enalapril maleate 
17 Right Right vestibular neuritis 
5/28/02 - 
7/2/02 N/A N/A 
18 Right Right labyrinthitis 
12/00 – 
2/13/01 
Colon surgery 
(95), gallbladder 
surgery (95), 
CABG (98), HTN 
Cardizem, 
Ecotrin, Seravent, 
Pravachol 
19 Left Left vestibular neuritis 
3/18/01 – 
5/24/01 
Colon surgery 
(95), pacemaker 
(01), HTN 
Aspirin, Tylenol, 
Atenolol, 
Larazepam, 
Coumadin, 
Prilosec, 
Probemacil, 
Cardura 
20 Right Right vestibular neuritis 
11/22/00 - 
4/4/01 
Arthroscopic 
surgery right knee 
Synthroid, 
Prevacid 
21 Left Left vestibular neuritis 
8/1/01 – 
9/24/01 GSW 1978 Diltizema 
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Appendix E. Consent Form – Subjects with UVH 
 
 
 
CHANGES IN GAIT, BALANCE, AND FUNCTION WITH VESTIBULAR 
REHABILITATION 
This is a clinical trial (a type of research study). Clinical trials include only 
patients who choose to take part.  You are being asked to take part in this study 
because you have an inner ear (vestibular) problem. 
 
WHY IS THIS STUDY BEING DONE? 
The purpose of this study is to help physical therapists determine the validity of 
walking (gait) measures taken with the GaitMat computerized system.  
Additionally, this study will add to the understanding of how vestibular problems 
affect a person’s gait. 
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY 
About 15 people will take part in this study. 
WHAT IS INVOLVED IN THE STUDY? 
You will be asked to complete a survey that asks how much your vestibular 
problem affects you.  This survey should take about 10 minutes to complete.  You 
will then be examined by a physical therapist.  The examination will include 
computerized balance testing with the EquiTest.  A support harness will be 
applied to keep you from falling during this test.  You will be asked to maintain 
your balance while standing on a platform with eyes open, eyes closed, and while 
the platform moves slightly.  The EquiTest will take about 30 minutes.  You will 
also be asked to walk back and forth across a mat that will measure your walking.  
This will take about five minutes.  The physical therapist may also examine your 
leg strength, eye control, and ability to balance in different circumstances.  
Overall, the physical therapy examination will take about one hour. 
 
After the examination, the physical therapist will determine what rehabilitation 
activities are best for you.  You will participate in a standard vestibular 
rehabilitation program that will probably include outpatient physical therapy visits 
and a home exercise program. 
 
When you are discharged from physical therapy, the physical therapist will again 
conduct the examination procedures as above. 
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All of these procedures are part of regular physical therapy care of patients with 
vestibular disorders, except for the use of the computerized mat to measure your 
walking.  Usually physical therapists visually analyze walking.  The computer 
will provide more precise information. 
 
HOW LONG WILL I BE IN THE STUDY? 
You will be in the study for four to six weeks.  You can stop participating at any 
time. 
 
WHAT ARE THE RISKS OF THE STUDY? 
The only risk associated with this study is the possibility of losing your balance 
when you walk on the mat.  The physical therapist will walk along side of you, 
and will provide physical support if needed.  There is only slightly more risk of 
falling when walking on the mat than when walking on level ground.  For more 
information about risks, ask the researcher. 
 
ARE THERE BENEFITS TO TAKING PART IN THE STUDY? 
If you agree to take part in this study, there may or may not be direct medical 
benefit to you. We hope the information learned from this study will benefit other 
patients with vestibular problems in the future. 
 
The possible benefits of taking part in the study are the same as receiving 
vestibular rehabilitation without being in the study. 
 
WHAT OTHER OPTIONS ARE THERE? 
Instead of being in this study, you have these options: 
• Participate in physical therapy without having computerized analysis of your 
walking.  You may receive physical therapy even if you do not take part in the 
study. 
 
WHAT ABOUT CONFIDENTIALITY? 
Efforts will be made to keep your personal information confidential. We cannot 
guarantee absolute confidentiality. Your personal information may be disclosed if 
required by law. 
 
WHAT ARE THE COSTS? 
Taking part in this study will not lead to added costs to you or your insurance 
company, beyond those involved in standard physical therapy care for a vestibular 
problem. 
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In the case of injury or illness resulting from this study, emergency medical 
treatment is available but will be provided at the usual charge.  No funds have 
been set aside to compensate you in the event of injury.  You or your insurance 
company will be charged for continuing medical care and/or hospitalization. 
 
You will receive no payment for taking part in this study. 
 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
Taking part in this study is voluntary. You may choose not to take part or may 
leave the study at any time. Leaving the study will not result in any penalty or loss 
of benefits to which you are entitled. 
 
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about the study or a research-related injury, contact the researcher 
Paul Vidal at (610) 237-4388 or Susan P. Barker at (570) 674-6422.  This study 
will take place at the Wellness Center of Mercy Fitzgerald Medical Center, 
Darby, PA. 
 
For questions about your rights as a research participant, contact Richard H. 
Hunn, M.D., the Chairman of the MCMC/MCH Institutional Review Board 
(which is a group of people who review the research to protect your rights) at 
(610) 237-4968. 
 
You will get a copy of this form. You may also request a copy of the protocol 
(full study plan). 
 
SIGNATURES 
I have explained to _________________________________________________ 
the purpose of the research, the procedures required, and the possible risks and 
benefits to the best of my ability. 
 
 
Investigator _____________________________________ Date ________________ 
 
I confirm that _____________________________________________________ 
has explained to me the purpose of the research, the study procedures that I will 
undergo, and the possible risks as well as benefits that I may experience.  
Alternatives to my participation in the study have also been discussed.  I have 
read and I understand this consent form.  Therefore, I agree to give my consent to 
participate as a subject in this research project. 
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Participant______________________________________ Date ________________ 
Witness ________________________________________ Date ________________ 
Revised 11/25/02 
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Appendix F. Consent Form – Subjects without Vestibular Pathology 
 
 
Drexel University 
Consent to Take Part  
In a Research Study 
 
1. Subject Name:  ____________________________________________________ 
  
2. Title of Research: Changes in Gait, Balance, and Function with Vestibular 
Rehabilitation – Normal Gait 
 
3. Investigator’s Name:  William Freedman, PhD 
 
4. Consenting for the Research Study: 
 
This is a long and an important document.  If you sign it, you will be authorizing 
the Philadelphia Health & Education Corporation (doing business as Drexel 
University College of Medicine) and its researchers to perform research studies 
on you.  You should take your time and carefully read it.  You can also take a 
copy of this consent form to discuss it with your family member, physician, 
attorney or any one else you would like before you sign it.  Do not sign it unless 
you are comfortable in participating in this study. 
 
5. Purpose of Research: 
 
You are being asked to participate in a research study.  The purpose of this study 
is to help physical therapists understand how normal people walk.  This data will 
be used to compare to a person with an inner ear problem, to investigate how 
inner ear problems affect a person’s walking.    
 
This study is being conducted in partial fulfillment of the requirements for the 
Ph.D. degree in Biomedical Science from Drexel University.  You are being 
asked to participate because you are the same age, gender, and height as another 
person who has an inner ear problem.  About 15 people with inner ear problems 
and 15 healthy people will take part in this study. 
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Taking part in this study is voluntary.  You may choose not to take part or may 
leave the study at any time.  Leaving the study will not result in any penalty or 
loss of benefits to which you are entitled. 
 
6. Procedures and Duration: 
 
The study involves only one session.  You will be asked to walk back and forth 
across a mat that will measure your walking.  Usually physical therapists visually 
analyze walking.  The computer will provide more precise information.  This 
procedure will take about fifteen minutes. 
 
7. Risks and Discomforts/Constraints: 
 
The only risk associated with this study is the possibility of losing your balance 
when you walk on the mat.  The physical therapist will walk along side of you, 
and will provide physical support if needed.  There is only slightly more risk of 
falling when walking on the mat than when walking on level ground.  For more 
information about risks, ask the researcher.   
 
8. Benefits: 
 
There will be no direct medical benefit to you as a result of participating in this 
study.  It is hoped that the information obtained will help physical therapists in 
making decisions about treatment of walking in patients with inner ear problems. 
 
9. In Case of Injury: 
   
If you have any questions or believe you have been injured in any way by being in 
this research study, you should contact Dr. Mari King at telephone (570) 674-
6400.  If you are injured by the research activity, we will reimburse you for the 
reasonable costs of medically necessary treatment that is not covered by your 
health insurance or plan.  This agreement to reimburse you does not include 
treatment for any injury that is not a result of the research activity.  No other 
payments will be made.  Drexel University will not be responsible for costs 
related to the injury. 
 
10. Confidentiality: 
 
In any publication or presentation of research results, your identity will be kept 
confidential, but there is a possibility that records which identify you may be 
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inspected by authorized individuals.  I consent to such inspections and to the 
copying of excerpts of my records, if required by any of these representatives. 
 
11. Consent: 
 
• I have been informed of the reasons for this study. 
• I have had the study explained to me. 
• I have had all of my questions answered. 
• I have carefully read this consent form, have initialed each page, and 
have received a signed copy. 
• I gave consent voluntarily. 
 
 
_____________________________________________________ ______________ 
Subject or Legally Authorized Representative    Date 
 
 
_____________________________________________________ ______________ 
Investigator or Individual Obtaining this Consent/Permission  Date 
 
 
_____________________________________________________ _______________ 
Witness to Signature        Date 
 
 
List of Individuals Authorized to Obtain Consent/Permission 
 
Name   Title    Day Phone #  24 Hr Phone# 
Susan Barker  Associate Professor  (570) 674-6422 (570)674-6422 
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Appendix G. Gait, EquiTest, and DHI Means and Standard Deviations 
 
Gait Speed 
UVH: Pre-VR UVH: Post-VR No Pathology Subject Pair* SSS FS HT SSS FS HT SSS FS HT 
11-31 1.30 1.70 1.39 0.89 1.14 0.96 0.89 2.29 1.13
12-32 0.66 0.87 0.48 0.85 0.90 0.79 1.32 1.75 1.06
13-33 0.68 1.42 0.89 0.84 1.49 0.95 1.03 1.92 1.09
14-34 0.75 1.24 0.72 0.86 1.43 0.93 1.12 1.69 1.23
15-35 0.85 1.62 0.76 1.09 1.60 0.87 0.95 1.50 1.20
16-36 0.66 0.98 0.52 0.87 1.02 0.85 1.28 2.07 1.44
17-37 0.80 1.17 0.70 0.96 1.34 0.87 1.10 1.86 1.27
18-38 0.71 1.17 0.63 0.86 1.18 0.63 0.89 1.24 0.92
19-39 0.68 1.30 0.50 0.74 0.84 0.65 0.87 1.52 0.94
20-40 0.63 0.95 0.44 0.59 0.99 0.53 0.87 1.22 0.70
21-41 0.95 1.23 0.75 1.04 1.26 0.60 0.70 1.54 0.89
Mean 0.79 1.24 0.71 0.87 1.20 0.79 1.00 1.69 1.08
SD 0.19 0.25 0.25 0.13 0.24 0.15 0.18 0.32 0.20
 * 11-21: Subjects with UVH 
 * 31-41: Subjects with No Pathology 
 
 
Support Base, m 
UVH: Pre-VR UVH: Post-VR No Pathology Subject 
Pair* SSS FS HT SSS FS HT SSS FS HT 
11-31 0.15 0.15 0.27 0.12 0.14 0.14 0.08 0.05 0.09
12-32 0.07 0.07 0.11 0.24 0.25 0.24 0.10 0.09 0.13
13-33 0.07 0.08 0.13 0.07 0.12 0.08 0.07 0.07 0.08
14-34 0.12 0.15 0.09 0.11 0.13 0.12 0.08 0.11 0.09
15-35 0.22 0.22 0.28 0.17 0.18 0.19 0.09 0.12 0.14
16-36 0.35 0.37 0.37 0.35 0.35 0.37 0.08 0.06 0.08
17-37 0.13 0.14 0.18 0.15 0.15 0.16 0.06 0.05 0.05
18-38 0.11 0.10 0.13 0.08 0.09 0.10 0.06 0.03 0.08
19-39 0.31 0.33 0.33 0.30 0.30 0.33 0.11 0.11 0.13
20-40 0.06 0.05 0.10 0.07 0.05 0.09 0.08 0.08 0.14
21-41 0.06 0.07 0.08 0.05 0.04 0.05 0.10 0.11 0.12
Mean 0.15 0.16 0.19 0.16 0.16 0.17 0.08 0.08 0.10
SD 0.10 0.10 0.10 0.096 0.095 0.099 0.015 0.029 0.03
 * 11-21: Subjects with UVH 
 * 31-41: Subjects with No Pathology 
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Double Support Time (% of Cycle Time) 
UVH: Pre-VR UVH: Post-VR No Pathology Subject 
Pair* SSS FS HT SSS FS HT SSS FS HT 
11-31 25.85 17.21 22.37 19.10 18.79 44.52 1.34 0.76 1.23
12-32 23.71 20.51 29.63 18.26 18.69 25.29 8.14 7.75 10.68
13-33 19.80 16.76 24.63 20.97 20.68 22.81 11.41 8.63 10.61
14-34 28.62 20.58 24.27 18.26 14.94 47.15 13.21 9.29 9.96
15-35 10.82 36.73 21.27 13.72 13.32 17.48 10.79 4.89 9.80
16-36 30.01 26.35 37.10 34.36 21.24 22.75 12.80 9.83 12.83
17-37 19.86 18.78 25.31 18.84 16.13 19.94 11.34 18.50 10.70
18-38 31.87 25.25 25.28 25.77 18.78 30.22 12.56 11.07 13.12
19-39 28.81 15.23 41.97 25.38 21.21 30.72 12.91 9.81 13.65
20-40 23.40 16.64 27.32 25.80 18.46 27.76 12.54 10.35 13.90
21-41 20.67 16.15 17.91 21.30 15.12 20.52 12.99 8.77 11.95
Mean 23.95 20.93 27.01 21.98 17.94 28.11 10.91 9.06 10.77
SD 5.77 6.09 6.67 5.30 2.57 9.27 3.33 4.09 3.33
* 11-21: Subjects with UVH 
* 31-41: Subjects with No Pathology 
 
 
HA-I: Time from Heel Contact to Forefoot Contact (% of Cycle Time) 
UVH: Pre-VR UVH: Post-VR No Pathology Subject 
Pair* SSS FS HT SSS FS HT SSS FS HT 
11-31 15.96 14.45 25.55 14.09 12.10 12.90 19.90 16.53 29.37
12-32 27.49 29.15 50.32 34.14 40.93 38.42 37.91 33.80 41.57
13-33 18.03 15.74 22.48 25.82 25.87 23.51 31.28 33.75 30.16
14-34 17.11 18.35 21.47 19.45 12.50 28.92 16.71 17.90 16.16
15-35 21.80 18.27 32.72 31.63 16.68 30.97 28.96 18.15 27.19
16-36 22.44 28.03 30.27 26.54 22.02 25.14 15.37 18.67 17.18
17-37 43.42 42.22 43.78 42.12 40.34 44.61 12.73 20.01 20.62
18-38 28.25 27.46 21.58 22.75 31.06 23.32 28.86 15.70 45.54
19-39 25.90 24.39 23.02 22.10 21.74 24.37 17.10 19.53 24.05
20-40 31.93 35.47 23.64 27.82 30.57 20.51 38.34 31.49 38.00
21-41 25.06 20.40 26.79 23.26 18.09 25.15 16.73 25.03 18.71
Mean 25.22 24.90 29.24 26.34 24.72 27.07 23.99 22.78 28.05
SD 7.47 8.24 9.16 7.25 9.61 8.20 8.90 6.69 9.59
* 11-21: Subjects with UVH 
* 31-41: Subjects with No Pathology 
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Dizziness Handicap Inventory Scores 
Pre-VR Post-VR Subject 
# DHI-
Total 
DHI-
Physical 
DHI-
Emotional 
DHI-
Functional  
DHI-
Total 
DHI-
Physical 
DHI-
Emotional 
DHI-
Functional 
11 86 28 26 32  76 20 32 24 
12 26 16 10 0  20 8 2 10 
13 22 10 10 2  8 0 4 4 
14 28 14 4 10  22 12 2 8 
15 42 18 2 22  10 6 0 4 
16 46 14 10 22  26 10 12 4 
17 70 26 12 32  32 12 8 12 
18 12 6 2 4  12 4 6 2 
19 60 24 14 22  42 20 12 10 
20 44 4 22 18  26 4 8 14 
21 40 16 10 14  2 0 0 2 
Mean 43.3 16.0 11.1 16.2  25.1 8.7 7.8 8.6 
SD 20.9 7.4 7.2 10.7  19.5 6.6 8.7 6.3 
 
 
 
EquiTest SOT-C Score 
 
Subject # Pre-VR  Post-VR
11 67 83 
12 59 82 
13 75 70 
14 57 61 
15 64 80 
16 48 72 
17 55 74 
18 65 79 
19 37 67 
20 56 70 
21 43 83 
Mean 56.9 74.6 
SD 10.5 7.0 
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Appendix H. ANOVA Tables and Pairwise Comparison Tables for Preliminary 
Analyses by Subject Group 
 
 
 
Notes:   
• All statistical analyses were performed with SPSS for Windows, version 11.0.1 
• All pairwise comparisons used a Bonferroni correction for repeated measures 
 
 
 
Table 26. — Results of 3-Way Repeated Measures ANOVA for Side, Trial, and 
Condition - Support Base, Subjects with UVH Before VR 
 
Source Sum of Squares 
degrees 
of 
freedom 
Mean 
Square F Sig. 
SIDE 1.370E-05 1 1.370E-05 .048 .832 
Error (SIDE) 2.877E-03 10 2.877E-04   
CONDITION 4.081E-02 2 2.041E-02 7.442    .004 * 
Error (COND) 5.484E-02 20 2.742E-03   
TRIAL 4.146E-03 3 1.382E-03 1.235 .314 
Error (TRIAL) 3.358E-02 30 1.119E-03   
SIDE*COND 2.458E-04 2 1.229E-04 .468 .633 
Error (SIDE*COND) 5.248E-03 20 2.624E-04   
SIDE*TRIAL 5.586E-04 3 1.862E-04 2.256 .102 
Error (SIDE*TRIAL) 2.476E-03 30 8.254E-05   
COND*TRIAL 3.943E-03 6 6.572E-04 .952 .466 
Error (COND*TRIAL) 4.144E-02 60 6.907E-04   
SIDE*COND*TRIAL 3.290E-04 6 5.483E-05 .569 .753 
Error (SIDE*COND*TRIAL) 5.777E-03 60 9.629E-05   
*Significant at α = 0.05  
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Table 27. — Pairwise Comparisons - Support Base by Condition, Subjects with 
UVH Before VR 
 
(I) Cond (J) Cond Mean Difference (I-
J) 
Std. Error Sig. N 
SSS FS -5.451E-03 .005 .840 11 
FS HT -2.322E-02 .010 .113 11 
HT SSS 2.868E-02 .008 .019* 11 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 28. — Results of 3-Way Repeated Measures ANOVA for Side, Trial, and 
Condition - Support Base, Subjects with UVH After VR 
 
Source SS df MS F Sig. 
SIDE 4.640E-08 1.000 4.640E-08 .000 .990 
Error (SIDE) 2.600E-03 10.000 2.600E-04   
CONDITION 1.383E-02 1.305 1.059E-02 6.056 .022 * 
Error (COND) 2.283E-02 13.050 1.749E-03   
TRIAL 1.851E-03 3 6.170E-04 .974 .418 
Error (TRIAL) 1.901E-02 30 6.337E-04   
SIDE*COND 1.480E-04 2 7.402E-05 .470 .632 
Error (SIDE*COND) 3.149E-03 20 1.574E-04   
SIDE*TRIAL 4.066E-04 1.870 2.174E-04 .959 .396 
Error (SIDE*TRIAL) 4.241E-03 18.704 2.268E-04   
COND*TRIAL 4.025E-03 6 6.708E-04 1.325 .260 
Error (COND*TRIAL) 3.037E-02 60 5.061E-04   
SIDE*COND*TRIAL 2.644E-04 6 4.407E-05 .487 .815 
Error (SIDE*COND*TRIAL) 5.429E-03 60 9.048E-05   
*Significant at α = 0.05  
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Table 29. — Pairwise Comparisons - Support Base by Condition, Subjects with 
UVH After VR 
 
(I) Cond (J) Cond Mean Difference (I-J) Std. Error Sig. 
SSS FS -1.121E-02 .005 .161 
FS HT -6.290E-03 .006 1.000 
HT SSS 1.750E-02 .003 .001* 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS= Fast speed 
HT = Head turning 
 
 
 
Table 30. — Results of 3-Way Repeated Measures ANOVA for Side, Trial, and 
Condition - Support Base, Subjects Without Vestibular Pathology 
 
Source SS df MS F Sig. 
SIDE 2.594E-04 1 2.594E-04 1.020 .336 
Error (SIDE) 2.543E-03 10 2.543E-04   
CONDITION 2.618E-02 2 1.309E-02 7.266 .004 * 
Error (COND) 3.604E-02 20 1.802E-03   
TRIAL 1.490E-03 3 4.967E-04 .740 .537 
Error (TRIAL) 2.014E-02 30 6.714E-04   
SIDE*COND 2.451E-04 2 1.225E-04 .667 .524 
Error (SIDE*COND) 3.675E-03 20 1.837E-04   
SIDE*TRIAL 4.225E-04 3 1.408E-04 .649 .590 
Error (SIDE*TRIAL) 6.513E-03 30 2.171E-04   
COND*TRIAL 1.803E-03 6 3.006E-04 .668 .676 
Error (COND*TRIAL) 2.699E-02 60 4.499E-04   
SIDE*COND*TRIAL 2.408E-03 2.978 8.088E-04 2.206 .108 
Error (SIDE*COND*TRIAL) 1.092E-02 29.778 3.666E-04   
*Significant at α = 0.05  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
99
 
Table 31. — Pairwise Comparisons - Support Base by Condition, Subjects Without 
Vestibular Pathology 
 
(I) Cond (J) Cond Mean Difference (I-J) Std. Error Sig. N 
SSS FS 3.636E-03 .006 1.000 11 
FS HT -2.271E-02 .007 .029* 11 
HT SSS 1.907E-02 .006 .027* 11 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 32. — Results of 3-Way Repeated Measures ANOVA for Side, Trial, and 
Condition - Double Support Time, Subjects with UVH Before VR 
 
Source SS df MS F Sig. 
SIDE 2.523E-05 1 2.523E-05 .018 .897 
Error (SIDE) 1.428E-02 10 1.428E-03   
CONDITION 7.685E-02 2 3.842E-02 17.996 .000 * 
Error (COND) 4.270E-02 20 2.135E-03   
TRIAL 4.245E-03 3 1.415E-03 1.320 .286 
Error (TRIAL) 3.216E-02 30 1.072E-03   
SIDE*COND 8.937E-04 2 4.468E-04 .546 .588 
Error (SIDE*COND) 1.638E-02 20 8.190E-04   
SIDE*TRIAL 1.886E-03 3 6.288E-04 1.421 .256 
Error (SIDE*TRIAL) 1.327E-02 30 4.424E-04   
COND*TRIAL 4.821E-03 6 8.036E-04 .671 .673 
Error (COND*TRIAL) 7.181E-02 60 1.197E-03   
SIDE*COND*TRIAL 1.368E-03 6 2.279E-04 .527 .786 
Error (SIDE*COND*TRIAL) 2.597E-02 60 4.328E-04   
*Significant at α = 0.05  
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Table 33. — Pairwise Comparisons – Double Support Time by Condition, 
Subjects with UVH Before VR 
 
(I) Cond (J) Cond Mean Difference (I-J) Std. Error Sig. N 
SSS FS 3.006E-02 .004 .000* 11 
FS HT -4.017E-02 .008 .002* 11 
HT SSS 1.011E-02 .008 .716 11 
*Significant at α = 0.05  
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 34. — Results of 3-Way Repeated Measures ANOVA for Side, Trial, and 
Condition - Double Support Time, Subjects with UVH After VR 
 
Source SS df MS F Sig. 
SIDE 7.034E-03 1.000 7.034E-03 1.547 .242 
Error (SIDE) 4.546E-02 10.000 4.546E-03   
CONDITION .140 1.088 .129 6.299 .027 * 
Error (COND) .222 10.880 2.043E-02   
TRIAL 5.348E-02 1.380 3.875E-02 1.583 .237 
Error (TRIAL) .338 13.800 2.448E-02   
SIDE*COND 1.109E-02 1.239 8.953E-03 .886 .388 
Error (SIDE*COND) .125 12.386 1.010E-02   
SIDE*TRIAL 3.612E-03 1.422 2.540E-03 .418 .599 
Error (SIDE*TRIAL) 8.648E-02 14.219 6.082E-03   
COND*TRIAL .102 1.409 7.267E-02 1.589 .236 
Error (COND*TRIAL) .644 14.088 4.572E-02   
SIDE*COND*TRIAL 2.213E-02 1.789 1.237E-02 1.523 .245 
Error (SIDE*COND*TRIAL) .145 17.887 8.123E-03   
*Significant at α = 0.05 
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Table 35. — Pairwise Comparisons – Double Support Time by Condition, 
Subjects with UVH After VR 
 
(I) Cond (J) Cond Mean Difference (I-J) Std. Error Sig. 
SSS FS 2.630E-02 .005 .001* 
 HT -3.007E-02 .020 .489 
FS SSS -2.630E-02 .005 .001* 
 HT -5.638E-02 .018 .035* 
HT SSS 3.007E-02 .020 .489 
 FS 5.638E-02 .018 .035* 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 36. — Results of 3-Way Repeated Measures ANOVA for Side, Trial, and 
Condition - Double Support Time, Subjects Without Vestibular Pathology 
 
Source SS df MS F Sig. 
SIDE 40.782 1.000 40.782 1.178 .303 
Error (SIDE) 346.336 10.000 34.634   
CONDITION 479.348 1.357 353.226 8.364   .008 * 
Error (COND) 573.082 13.571 42.230   
TRIAL 100.433 1.556 64.540 3.033 .087 
Error (TRIAL) 331.146 15.561 21.280   
SIDE*COND 51.629 1.193 43.275 1.017 .349 
Error (SIDE*COND) 507.626 11.930 42.549   
SIDE*TRIAL 29.572 1.341 22.057 1.040 .350 
Error (SIDE*TRIAL) 284.361 13.407 21.210   
COND*TRIAL 61.109 1.789 34.155 .859 .429 
Error (COND*TRIAL) 711.382 17.892 39.761   
SIDE*COND*TRIAL 36.478 1.567 23.978 .657 .496 
Error (SIDE*COND*TRIAL) 571.707 15.673 36.478   
*Significant at α = 0.05  
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Table 37. — Pairwise Comparisons – Double Support Time by Condition, 
Subjects Without Vestibular Pathology 
 
(I) Cond (J) Cond Mean Difference (I-J) Std. Error Sig. 
SSS FS 2.937 .935 .031* 
FS HT -2.773 .936 .043* 
HT SSS -.163 .451 1.000 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 38. — Results of 2-Way Repeated Measures ANOVA for Condition and Trial 
– Speed, Subjects with UVH Before VR 
 
Source SS Df MS F Sig. 
CONDITION 7.207 2 3.603 70.452   .000 * 
Error (COND) 1.023 20 5.115E-02   
TRIAL 6.307E-02 1.468 4.296E-02 .983 .372 
Error (TRIAL) .642 14.681 4.371E-02   
COND*TRIAL .117 3.300 3.532E-02 .636 .612 
Error (COND*TRIAL) 1.833 33.003 5.554E-02   
Significant at α = 0.05  
 
 
 
Table 39. — Pairwise Comparisons – Speed by Condition, Subjects with UVH 
Before VR 
 
(I) Cond (J) 
Cond 
Mean Difference (I-J) Std. Error Sig. N 
SSS FS -.451 .056 .000* 11 
FS HT .531 .048 .000* 11 
HT SSS -7.964E-02 .040 .214 11 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
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Table 40. — Results of 2-Way Repeated Measures ANOVA for Condition and 
Trial – Speed, Subjects with UVH After VR 
 
Source SS df MS F Sig. 
CONDITION 4.184 2 2.092 28.623 .000 * 
Error (COND) 1.462 20 7.308E-02   
TRIAL .101 3 3.362E-02 1.463 .244 
Error (TRIAL) .689 30 2.297E-02   
COND*TRIAL .130 6 2.170E-02 1.447 .212 
Error (COND*TRIAL) .900 60 1.500E-02   
*Significant at α = 0.05  
 
 
 
Table 41. — Pairwise Comparisons – Speed by Condition, Subjects with UVH After 
VR 
 
(I) Cond (J) 
Cond 
Mean Difference (I-J) Std. Error Sig. 
SSS FS -.327 .058 .001* 
FS HT .413 .065 .000* 
HT SSS -8.566E-02 .049 .325 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 42. — Results of 2-Way Repeated Measures ANOVA for Condition and Trial 
– Speed, Subjects Without Vestibular Pathology 
 
Source SS df MS F Sig. 
CONDITION 12.930 2 6.465 58.832 .000 * 
Error (COND) 2.198 20 .110   
TRIAL 8.004E-02 3 2.668E-02 1.300 .293 
Error (TRIAL) .616 30 2.052E-02   
COND*TRIAL .162 1.437 .113 1.428 .264 
Error (COND*TRIAL) 1.132 14.371 7.879E-02   
*Significant at α = 0.05  
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Table 43. — Pairwise Comparisons – Speed by Condition, Subjects Without 
Vestibular Pathology 
 
(I) Cond (J) 
Cond 
Mean Difference (I-J) Std. Error Sig. 
SSS FS -.694 .087 .000* 
FS HT .629 .072 .000* 
HT SSS 6.568E-02 .046 .564 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
 
 
 
Table 44. — Results of 2-Way Repeated Measures ANOVA for Side and Condition 
− HA-I, Subjects with UVH Before VR 
 
Source SS df MS F Sig. 
SIDE 5.100 1.000 5.100 .105 .752 
Error (SIDE) 484.241 10.000 48.424   
CONDITION 156.467 1.264 123.810 2.127 .168 
Error (COND) 735.730 12.638 58.217   
SIDE*COND 13.222 2 6.611 .704 .506 
Error (SIDE*COND) 187.692 20 9.385   
 
 
 
Table 45. — Results of 2-Way Repeated Measures ANOVA for Side and Condition 
− HA-I, Subjects with UVH After VR 
 
Source SS df MS F Sig. 
SIDE 1.679 1.000 1.679 .031 .864 
Error (SIDE) 541.141 10.000 54.114   
CONDITION 989.234 1.061 932.001 1.493 .251 
Error (COND) 6624.618 10.614 624.134   
SIDE*COND 9.349 2 4.674 .228 .798 
Error (SIDE*COND) 410.456 20 20.523   
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Table 46. — Results of 2-Way Repeated Measures ANOVA for Side and 
Condition − HA-I, Subjects Without Vestibular Pathology 
 
Source SS df MS F Sig. 
SIDE 1.200 1.000 1.200 .040 .845 
Error (SIDE) 299.577 10.000 29.958   
CONDITION 299.741 1.322 226.724 2.534 .130 
Error (COND) 1182.649 13.221 89.456   
SIDE*COND 56.788 2 28.394 2.940 .076 
Error (SIDE*COND) 193.157 20 9.658   
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Appendix I. ANOVA Tables and Pairwise Comparison Tables for Analyses 
Between Groups 
 
 
 
Table 47. — Results of 2-Way ANOVA for Category and Condition – Speed 
 
Source SS df MS F Sig. 
CATEGORY 2.364 2 1.182 15.794 .000 * 
Error (CAT) 1.497 20 7.483E-02   
CONDITION 5.605 1.257 4.459 140.773 .000 * 
Error (COND) .398 12.569 3.168E-02   
CAT*COND .386 2.116 .182 4.807 .018 * 
Error (CAT*COND) .802 21.165 3.791E-02   
*Significant at α = 0.05  
 
 
 
Table 48. — Summary of Results of One-Way ANOVAs for Speed 
 
Factor Significant Difference Between: 
UVH pre-VR SSS and FS 
 FS and HT 
  
UVH post-VR SSS and FS 
 FS and HT 
  
No vestibular pathology SSS and FS 
 FS and HT 
  
Self-selected speed No effect 
  
Fast speed UVH pre-VR and No pathology 
 UVH post-VR and No pathology 
  
Head turning UVH pre-VR and No pathology 
 UVH post-VR and No pathology 
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Table 49. — Results of 2-Way Repeated Measures ANOVA for Category and 
Condition – Support Base 
 
Source SS df MS F Sig. 
CATEGORY .124 2 6.180E-02 5.115 .016 * 
Error (CAT) .242 20 1.208E-02   
CONDITION 1.211E-02 1.375 8.803E-03 14.622 .001 * 
Error (COND) 8.280E-03 13.754 6.021E-04   
CAT*COND 2.386E-03 1.731 1.379E-03 2.347 .131 
Error (CAT*COND) 1.017E-02 17.308 5.875E-04   
*Significant at α = 0.05  
 
 
 
Table 50. — Pairwise Comparisons – Support Base by Category 
 
(I) CAT (J) CAT Mean Difference (I-J) Std. Error Sig. N 
UVHpre UVHpost 6.336E-04 .018 1.000 11 
UVHpost No Path 7.464E-02 .030 .099 11 
No Path UVHpre -7.527E-02 .031 .110 11 
UVHpre = UVH, Before VR 
UVHpost = UVH, After VR 
No Path = Without vestibular pathology 
 
 
 
Table 51. — Pairwise Comparisons - Support Base by Condition 
 
(I) COND (J) COND Mean Difference (I-J) Std. Error Sig. 
SSS FS -4.866E-03 .004 .625 
FS HT -2.064E-02 .006 .028* 
HT SSS 2.551E-02 .005 .001* 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
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Table 52. — Results of 2-Way Repeated Measures ANOVA for Category and 
Condition – Double Support Time 
 
Source SS df MS F Sig. 
CATEGORY 3786.211 2 1893.105 55.323 .000 * 
Error (CAT) 684.386 20 34.219   
CONDITION 590.739 2 295.370 12.042 .000 * 
Error (COND) 490.547 20 24.527   
CAT*COND 212.092 2.174 97.540 1.710 .203 
Error (CAT*COND) 1240.292 21.744 57.040   
*Significant at α = 0.05  
 
 
 
Table 53. — Pairwise Comparisons – Double Support Time by Category 
 
(I) CAT (J) CAT Mean Difference (I-J) Std. Error Sig. N 
UVHpre UVHpost 1.284 1.180 .907 11 
UVHpost No Path 12.430 1.735 .000* 11 
No Path UVHpre -13.713 1.349 .000* 11 
*Significant at α = 0.05 
UVHpre = UVH before VR 
UVHpost = UVH after VR 
No Path = Without vestibular pathology 
 
 
 
Table 54. — Pairwise Comparisons – Double Support Time by Condition 
 
(I) COND (J) COND Mean Difference (I-J) Std. Error Sig. N 
SSS FS 2.970 1.204 .100 11 
FS HT -5.983 1.421 .005* 11 
HT SSS 3.013 .996 .038* 11 
*Significant at α = 0.05 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
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Table 55. — Results of 2-Way Repeated Measures ANOVA for Category and 
Condition – HA-I 
 
Source SS df MS F Sig. 
CATEGORY 40.386 1.175 34.377 .202 .701 
Error (CAT) 2001.388 11.748 170.360   
CONDITION 282.005 2 141.003 5.887 .010 * 
Error (COND) 479.045 20 23.952   
CAT*COND 46.226 2.062 22.422 .409 .676 
Error (CAT*COND) 1130.286 20.616 54.825   
*Significant at α = 0.05  
 
 
 
Table 56. — Pairwise Comparisons – HA-I by Condition 
 
(I) COND (J) COND Mean Difference (I-J) Std. Error Sig. N 
SSS FS 1.049 .958 .898 11 
SSS HT -2.939 1.138 .082 11 
HT FS 3.987 1.464 .064 11 
SSS = Self-selected speed 
FS = Fast speed 
HT = Head turning 
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Appendix J. Effect Sizes 
 
 
 
Subject DHI SOT-C
Speed: 
SSS 
Speed: 
FS 
Speed: 
HT 
BOS: 
SSS 
BOS: 
FS 
BOS: 
HT 
11 -0.46 1.45 -0.43 -0.45 -0.58 -0.32 -0.14 -1.21
12 -0.27 2.08 0.20 0.03 0.42 1.73 1.68 1.33
13 -0.64 -0.45 0.17 0.06 0.08 0.05 0.38 -0.52
14 -0.27 0.36 0.12 0.15 0.29 -0.18 -0.15 0.26
15 -1.46 1.45 0.25 -0.02 0.14 -0.47 -0.35 -0.79
16 -0.91 2.17 0.22 0.03 0.44 0.02 -0.21 0.03
17 -1.73 1.72 0.17 0.13 0.22 0.23 0.11 -0.15
18 0.00 1.27 0.15 0.00 -0.01 -0.29 -0.05 -0.23
19 -0.82 2.71 0.06 -0.37 0.20 -0.12 -0.21 0.02
20 -0.82 1.27 -0.05 0.04 0.12 0.09 -0.01 -0.09
21 -1.73 3.62 0.09 0.02 -0.20 -0.15 -0.22 -0.28
Mean -0.83 1.60 0.09 -0.03 0.10 0.05 0.08 -0.15
 
 
 
Subject 
DST-
CT: 
SSS 
DST-
CT: 
FS 
DST-
CT: 
HT 
HA-I: 
SSS 
HA-I: 
FS 
HA-I: 
HT 
11 -1.12 0.25 3.17 -0.24 -0.27 -1.32 
12 -0.90 -0.28 -0.62 0.85 1.36 -1.24 
13 0.19 0.61 -0.26 0.99 1.17 0.11 
14 -1.71 -0.88 3.27 0.30 -0.68 0.78 
15 0.48 -3.67 -0.54 1.26 -0.18 -0.18 
16 0.72 -0.80 -2.05 0.52 -0.70 -0.53 
17 -0.17 -0.42 -0.77 -0.17 -0.22 0.09 
18 -1.01 -1.01 0.71 -0.70 0.42 0.18 
19 -0.57 0.94 -1.61 -0.49 -0.31 0.14 
20 0.40 0.28 0.06 -0.52 -0.57 -0.32 
21 0.11 -0.15 0.37 -0.23 -0.27 -0.17 
Mean -0.33 -0.47 0.16 0.14 -0.02 -0.23 
 
 
 
0.2 Small 
0.5 Moderate 
0.8 Large 
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Appendix K. Raw Data Used in Preliminary Analyses by Groups 
 
 
 
Raw GM Data by Side 
 
Table 57. — Support Base by Side, m 
 
  SSS: 
Affected 
SSS: 
Unaff. 
FS: 
Affected 
FS: 
Unaff. 
HT: 
Affected 
HT: 
Unaff. 
Mean 0.15 0.15 0.16 0.15 0.18 0.18 UVH Pre-
VR SD 0.10 0.10 0.11 0.11 0.10 0.10 
 % Diff  0.00  6.02  0.00 
Mean 0.16 0.15 0.17 0.16 0.17 0.17 UVH 
Post-VR SD 0.10 0.10 0.09 0.10 0.10 0.10 
 % Diff  4.44  4.44  0.00 
Mean 0.08 0.08 0.08 0.08 0.10 0.10 No 
Pathology SD 0.02 0.02 0.03 0.04 0.04 0.03 
 % Diff  0.00  0.00  0.00 
 
 
 
Table 58. — Double Support Time by Side (% of Cycle Time) 
 
  SSS: 
Affected 
SSS: 
Unaff. 
FS: 
Affected 
FS: 
Unaff. 
HT: 
Affected 
HT: 
Unaff. 
Mean 13.40 12.59 12.37 11.78 15.01 13.57 UVH 
Pre-VR SD 6.16 7.34 4.96 6.15 12.47 9.31 
 % Diff  6.08  4.77  9.61 
Mean 10.49 10.69 11.11 10.05 10.47 13.34 UVH 
Post-VR SD 1.42 5.80 1.73 2.14 2.61 13.69 
 % Diff  1.86  9.53  27.35 
Mean 11.87 11.79 9.91 7.88 11.79 11.55 No 
Pathology SD 2.54 2.53 8.15 2.89 1.96 1.72 
 % Diff  0.69  20.51  2.06 
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Table 59. — HA-I by Side: Means and Standard Deviations (% of Cycle Time) 
 
  SSS: 
Affected 
SSS: 
Unaff. 
FS: 
Affected 
FS: 
Unaff. 
HT: 
Affected 
HT: 
Unaff. 
Mean 25.94 25.70 25.48 25.58 28.03 29.83 UVH 
Pre-VR SD 8.5 8.9 8.0 10.2 9.1 10.8 
 % Diff  -0.93  0.41  6.44 
Mean 27.42 27.36 23.72 22.65 32.47 32.94 UVH 
Post-VR SD 10.3 10.6 8.5 9.9 24.0 27.4 
 % Diff  -0.22  -4.50  1.43 
Mean 23.82 24.41 23.98 21.83 26.73 29.09 No 
Pathology SD 9.19 10.00 8.32 6.55 9.88 10.31 
  % Diff  -0.69  8.97  -8.83 
 
 
 
Raw GM Data by Trial 
 
Table 60. — Support Base by Trial, Self-Selected Speed, m 
 
 Trial 1 Trial 2 Trial 3 Trial 4 
Mean 0.15 0.15 0.14 0.15 UVH Pre-VR SD 0.11 0.10 0.10 0.10 
 % Diff  0.00 6.67 0.00 
Mean 0.16 0.16 0.15 0.15 UVH Post-VR SD 0.11 0.10 0.10 0.09 
 % Diff  0.00 -6.25 -6.25 
Mean 0.07 0.08 0.09 0.09 No Pathology SD 0.03 0.02 0.02 0.02 
 % Diff  14.29 28.57 28.57 
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Table 61. — Support Base by Trial, Fast Speed, m 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 0.15 0.17 0.15 0.15 UVH Pre-VR SD 0.09 0.11 0.11 0.12 
 % Diff  11.29 0.00 0.00 
Mean 0.17 0.17 0.16 0.16 UVH Post-VR SD 0.10 0.10 0.11 0.09 
 % Diff  0.00 3.23 3.23 
Mean 0.08 0.07 0.09 0.08 No Pathology SD 0.04 0.03 0.03 0.04 
 % Diff   -12.5 12.5 0.00 
 
 
 
Table 62. — Support Base by Trial, Head Turning, m 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 0.18 0.18 0.17 0.18 UVH Pre-VR SD 0.11 0.10 0.10 0.09 
 % Diff  0.00 -5.56 0.00 
Mean 0.17 0.17 0.16 0.16 UVH Post-VR SD 0.10 0.10 0.11 0.09 
 % Diff  0.00 -5.88 -5.88 
Mean 0.10 0.10 0.11 0.10 No Pathology SD 0.03 0.04 0.04 0.04 
 % Diff  0.00 10.00 0.00 
 
 
 
Table 63. — Double Support Time by Trial, Self-Selected Speed (% of Cycle Time) 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 13.14 12.91 12.54 13.38 UVH Pre-VR SD 6.83 7.29 6.60 6.71 
 % Diff  -1.74 -4.60 1.78 
Mean 10.34 10.65 9.89 11.49 UVH Post-VR SD 1.79 2.17 1.88 7.75 
 % Diff  3.07 -4.31 11.15 
Mean 12.47 11.47 12.22 11.17 No Pathology SD 3.43 1.91 2.47 1.91 
 % Diff  -8.07 -6.58 -8.62 
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Table 64. — Double Support Time by Trial, Fast Speed (% of Cycle Time) 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 12.79 12.71 11.86 10.92 UVH Pre-VR SD 4.79 5.84 5.50 6.21 
 % Diff  -0.67 -7.28 -14.64 
Mean 10.65 10.78 10.89 9.99 UVH Post-VR SD 2.03 1.98 2.16 1.86 
 % Diff  1.19 2.23 -6.22 
Mean 9.56 8.15 10.41 7.46 No Pathology SD 4.28 3.05 10.75 2.96 
 % Diff  -14.71 27.75 -28.33 
 
 
 
Table 65. — Double Support Time by Trial, Head Turning (% of Cycle Time) 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 14.57 14.24 14.71 13.64 UVH Pre-VR SD 8.81 10.90 14.98 8.78 
 % Diff  -2.23 0.97 -6.33 
Mean 10.18 15.06 12.36 10.02 UVH Post-VR SD 2.75 15.72 11.33 2.32 
 % Diff  47.99 21.41 -1.56 
Mean 12.44 11.61 11.26 11.36 No Pathology SD 1.87 1.81 1.83 1.70 
 % Diff  -6.65 -3.02 -0.87 
 
 
 
Table 66. — Speed by Trial, Self-Selected Speed, m/s 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 0.73 0.78 0.81 0.83 UVH Pre-VR SD 0.26 0.22 0.24 0.26 
 % Diff  6.44 10.25 13.77 
Mean 0.89 0.85 0.79 0.95 UVH Post-VR SD 0.17 0.15 0.19 0.16 
 % Diff  -4.75 -11.87 6.13 
Mean 1.01 0.97 1.01 1.02 No Pathology SD 0.22 0.18 0.20 0.19 
 % Diff  -3.42 0.00 0.99 
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Table 67. — Speed by Trial, Fast Speed, m/s 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 1.22 1.18 1.32 1.24 UVH Pre-VR SD 0.26 0.35 0.28 0.34 
 % Diff  -3.02 8.11 1.88 
Mean 1.24 1.17 1.19 1.19 UVH Post-VR SD 0.24 0.36 0.28 0.24 
 % Diff  -5.64 -3.55 -3.40 
Mean 1.71 1.71 1.60 1.77 No Pathology SD 0.35 0.34 0.47 0.35 
 % Diff  0.00 -6.12 3.62 
 
 
 
Table 68. — Speed by Trial, Head Turning, m/s 
 
  Trial 1 Trial 2 Trial 3 Trial 4 
Mean 0.73 0.70 0.69 0.71 UVH Pre-VR SD 0.43 0.22 0.22 0.25 
 % Diff  -4.09 -5.67 -2.34 
Mean 0.83 0.74 0.80 0.76 UVH Post-VR SD 0.19 0.14 0.20 0.18 
 % Diff  -10.42 -3.66 -8.63 
Mean 1.00 1.09 1.09 1.10 No Pathology SD 0.23 0.22 0.21 0.20 
 % Diff  8.83 8.83 10.19 
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